1
|
Suter P, Duerig M, Haefliger E, Chuard C. Identification of Francisella tularensis in ascites in the context of typhoidal tularaemia. BMJ Case Rep 2024; 17:e256509. [PMID: 38553022 PMCID: PMC10982718 DOI: 10.1136/bcr-2023-256509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/02/2024] Open
Abstract
Tularaemia is a highly infectious, zoonotic disease caused by Francisella tularensis, which has become increasingly prevalent over the past decade. Depending on the route of infection, different clinical manifestations can be observed. We report a case of typhoidal tularaemia presenting as a febrile illness with gastrointestinal symptoms in a patient in her mid-80s. During the acute illness phase and in the context of alcohol-related liver cirrhosis, the patient developed progressive ascites. During paracentesis, spontaneous bacterial peritonitis was consistently reported. Blood culture revealed Gram-negative bacilli identified as F. tularensis upon microscopic examination. Immediate clinical improvement was observed after adaptation to a pathogen-specific antibiotic regime. Typhoidal tularaemia presents general, non-specific symptoms without the local manifestations seen in other forms of the disease, thus representing a diagnostic challenge. In the case of protracted fever and if the epidemiological context as well as possible exposure are compatible, tularaemia should be considered in the differential diagnosis.
Collapse
Affiliation(s)
- Philipp Suter
- Department of Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- Division of Internal Medicine, University and Hospital of Fribourg, Fribourg, Switzerland
| | - Marco Duerig
- Division of Internal Medicine, University and Hospital of Fribourg, Fribourg, Switzerland
- Division of Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Emmanuel Haefliger
- Division of Internal Medicine, University and Hospital of Fribourg, Fribourg, Switzerland
- Division of Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Christian Chuard
- Departement of Infectiology, University and Hospital of Fribourg, Fribourg, Switzerland
| |
Collapse
|
2
|
Vacca M, Wilhelms B, Zange S, Avsar K, Gesierich W, Heiß-Neumann M. Thoracic manifestations of tularaemia: a case series. Infection 2024:10.1007/s15010-024-02204-1. [PMID: 38457094 DOI: 10.1007/s15010-024-02204-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2024] [Accepted: 01/31/2024] [Indexed: 03/09/2024]
Abstract
BACKGROUND Tularaemia is a zoonotic disease caused by Francisella tularensis, a highly virulent bacterium that affects humans and small wild animals. It is transmitted through direct contact with infected animals or indirectly through contaminated soil, water or arthropod bites (e.g. ticks). Primary thoracic manifestations of tularaemia are infrequent and, therefore, a diagnostic challenge for clinicians. METHODS We report six tularaemia cases with exclusively thoracic involvement diagnosed in a clinic for pulmonary diseases in Bavaria between 10/2020 and 02/2022. RESULTS All patients lived or were active in rural areas, four reported a recent tick bite. All patients presented with thoracic lymphadenopathy and pulmonary tumours or consolidations; all underwent bronchoscopy with EBUS-TBNA of lymph nodes, three lung biopsies as well. Five patients showed inflammatory changes in the endobronchial mucosa. The main histological findings were necrotic epithelioid granulomas with remarkable granulocyte infiltration. All cases were identified by positive serology, five by PCR (here identification of F.t. ssp. Holarctica) from biopsy as well. As first-line therapy, oral ciprofloxacin was given (5/6); in 2/6 cases, a combination of quinolone-rifampicin was given. CONCLUSIONS Pulmonary tularaemia may occur after tick bites and without extrathoracic manifestations. In patients who present with thoracic lymphadenopathy and pulmonary consolidations and who are exposed to increased outdoor activities, tularaemia should be included in the diagnostic pathway. Histologically, the presence of neutrophil-granulocyte infiltrations might help to distinguish tularaemia from other granulomatous infections, e.g. tuberculosis. The combination of quinolone-rifampicin rather than i.v. gentamicin reduced length of hospital stay in two patients.
Collapse
Affiliation(s)
- M Vacca
- Department of Pneumology, Asklepios Lung Clinic Munich-Gauting, Gauting, Germany.
| | - B Wilhelms
- Department of Pneumology, Asklepios Lung Clinic Munich-Gauting, Gauting, Germany
- Department of Internal Medicine, Krankenhaus Barmherzige Brüder, Munich, Germany
| | - S Zange
- Bundeswehr Institute of Microbiology, Munich, Germany
| | - K Avsar
- Department of Pneumology, Asklepios Lung Clinic Munich-Gauting, Gauting, Germany
- Lungenaerzte am Rundfunkplatz, Munich, Germany
| | - W Gesierich
- Department of Pneumology, Asklepios Lung Clinic Munich-Gauting, Gauting, Germany
| | - M Heiß-Neumann
- Department of Pneumology, Asklepios Lung Clinic Munich-Gauting, Gauting, Germany
| |
Collapse
|
3
|
Kimmich M, Jakob M. [Carcinoma, tuberculosis, atypical pneumonia - or may be pulmonary tularemia? Two case reports]. Pneumologie 2024; 78:199-203. [PMID: 37857320 DOI: 10.1055/a-2161-5792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2023]
Abstract
Tularemia is a rare zoonotic disease, endemic in rural areas all over Germany. It's clinical manifestation following inhalation of infectious aerosols may resemble pulmonary neoplasia, other atypical pneumonias or tuberculosis. Here we describe two representative cases with pulmonary tularemia.
Collapse
Affiliation(s)
- Martin Kimmich
- RBK Lungenzentrum Stuttgart, Abt. für Hämatologie, Onkologie, Pneumologische Onkologie, Palliativmedizin, Robert-Bosch-Krankenhaus GmbH, Stuttgart, Deutschland
| | - Maja Jakob
- RBK Lungenzentrum Stuttgart, Abt. für Hämatologie, Onkologie, Pneumologische Onkologie, Palliativmedizin, Robert-Bosch-Krankenhaus GmbH, Stuttgart, Deutschland
| |
Collapse
|
4
|
Bacterial agents (3rd section). Transfusion 2024; 64 Suppl 1:S208-S242. [PMID: 38394040 DOI: 10.1111/trf.17693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Accepted: 12/13/2023] [Indexed: 02/25/2024]
|
5
|
Birn R, Hamik J, Dayne L, Frederick J, Bartling A, Iwen PC, Wells A, Donahue M. Confirmed Case of Longstanding Respiratory Francisella tularensis holarctica Infection: Nebraska, 2022. Clin Infect Dis 2024; 78:S64-S66. [PMID: 38294112 PMCID: PMC10828931 DOI: 10.1093/cid/ciad669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2024] Open
Abstract
A male patient with distant history of extensive rabbit contact and pulmonary nodules for 6 years developed empyema. Francisella tularensis holarctica was isolated from thoracentesis fluid. Retrospective immunohistochemical examination of a pulmonary nodule, biopsied 3 years prior, was immunoreactive for F. tularensis. These findings suggest the potential for chronic tularemia.
Collapse
Affiliation(s)
- Rachael Birn
- Epidemiology Unit, Nebraska Department of Health and Human Services, Lincoln, Nebraska, USA
- Applied Epidemiology Fellow, Council of State and Territorial Epidemiologists, Atlanta, Georgia, USA
- Water, Climate and Health Program, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Jeff Hamik
- Epidemiology Unit, Nebraska Department of Health and Human Services, Lincoln, Nebraska, USA
- Department of Educational Psychology, University of Nebraska, Lincoln, Nebraska, USA
| | - Lana Dayne
- Communicable Disease Epidemiology Section, Douglas County Health Department, Omaha, Nebraska, USA
| | - Justin Frederick
- Communicable Disease Epidemiology Section, Douglas County Health Department, Omaha, Nebraska, USA
| | - Amanda Bartling
- Department of Pathology and Microbiology, Nebraska Public Health Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Peter C Iwen
- Department of Pathology and Microbiology, Nebraska Public Health Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Adam Wells
- Pulmonary and Critical Care Medicine Section, Nebraska Methodist Hospital, Omaha, Nebraska, USA
- Respiratory Care Program, Nebraska Methodist College, Omaha, Nebraska, USA
| | - Matthew Donahue
- Epidemiology Unit, Nebraska Department of Health and Human Services, Lincoln, Nebraska, USA
| |
Collapse
|
6
|
Marx GE, Curren E, Olesen M, Cronquist L, Schlosser L, Nichols M, Bye M, Cote A, McCormick DW, Nelson CA. Tularemia From Veterinary Occupational Exposure. Clin Infect Dis 2024; 78:S71-S75. [PMID: 38294113 DOI: 10.1093/cid/ciad687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2024] Open
Abstract
Tularemia is a disease caused by Francisella tularensis, a highly infectious bacteria that can be transmitted to humans by direct contact with infected animals. Because of the potential for zoonotic transmission of F. tularensis, veterinary occupational risk is a concern. Here, we report on a human case of tularemia in a veterinarian after an accidental needlestick injury during abscess drainage in a sick dog. The veterinarian developed ulceroglandular tularemia requiring hospitalization but fully recovered after abscess drainage and a course of effective antibiotics. To systematically assess veterinary occupational transmission risk of F. tularensis, we conducted a survey of veterinary clinical staff after occupational exposure to animals with confirmed tularemia. We defined a high-risk exposure as direct contact to the infected animal's body fluids or potential aerosol inhalation without use of standard personal protective equipment (PPE). Survey data included information on 20 veterinary occupational exposures to animals with F. tularensis in 4 states. Veterinarians were the clinical staff most often exposed (40%), followed by veterinarian technicians and assistants (30% and 20%, respectively). Exposures to infected cats were most common (80%). Standard PPE was not used during 80% of exposures; a total of 7 exposures were categorized as high risk. Transmission of F. tularensis in the veterinary clinical setting is possible but overall risk is likely low. Veterinary clinical staff should use standard PPE and employ environmental precautions when handling sick animals to minimize risk of tularemia and other zoonotic infections; postexposure prophylaxis should be considered after high-risk exposures to animals with suspected or confirmed F. tularensis infection to prevent tularemia.
Collapse
Affiliation(s)
- Grace E Marx
- Centers for Disease Control and Prevention, Division of Vector-Borne Diseases, Fort Collins, Colorado, USA
| | - Emily Curren
- Wyoming Department of Public Health, Cheyenne, Wyoming, USA
| | | | - Laura Cronquist
- North Dakota Department of Health and Human Services, Bismarck, North Dakota, USA
| | - Levi Schlosser
- North Dakota Department of Health and Human Services, Bismarck, North Dakota, USA
| | - Matthew Nichols
- Oklahoma State Department of Health, Oklahoma City, Oklahoma, USA
| | - Maria Bye
- Minnesota Department of Health, St Paul, Minnesota, USA
| | - Andrea Cote
- Wyoming Department of Public Health, Cheyenne, Wyoming, USA
- Centers for Disease Control and Prevention, Division of Foodborne, Waterborne, and Environmental Diseases, Atlanta, Georgia, USA
| | - David W McCormick
- Centers for Disease Control and Prevention, Division of Vector-Borne Diseases, Fort Collins, Colorado, USA
| | - Christina A Nelson
- Centers for Disease Control and Prevention, Division of Vector-Borne Diseases, Fort Collins, Colorado, USA
| |
Collapse
|
7
|
Williams MS. Efficacy of Doxycycline and Ciprofloxacin for Treatment of Pneumonic Tularemia in Cynomolgus Macaques. Clin Infect Dis 2024; 78:S7-S14. [PMID: 38294111 DOI: 10.1093/cid/ciad668] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2024] Open
Abstract
BACKGROUND The incidence of pneumonic tularemia is very low; therefore, it is not feasible to conduct clinical efficacy testing of tularemia medical countermeasures (MCMs) in humans. The US Food and Drug Administration's Animal Model Qualification Program under the Drug Development Tools Program is a regulatory pathway for animal models used in MCM efficacy testing and approval under the Animal Rule. The National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority worked together to qualify the cynomolgus macaque model of pneumonic tularemia. METHODS Using the model parameters and end points defined in the qualified model, efficacy of the antibiotics doxycycline and ciprofloxacin was evaluated in separate studies. Antibiotic administration, aimed to model approved human dosing, was initiated at time points of 24 hours or 48 hours after onset of fever as an indicator of disease. RESULTS Upon aerosol exposure (target dose of 1000 colony-forming units) to Francisella tularensis SchuS4, 80% of vehicle-treated macaques succumbed or were euthanized. Ciprofloxacin treatment led to 10 of 10 animals surviving irrespective of treatment time. Doxycycline administered at 48 hours post-fever led to 10 of 10 animals surviving, while 9/10 animals survived in the group treated with doxycycline 24 hours after fever. Selected surviving animals in both the placebo and doxycycline 48-hour group showed residual live bacteria in peripheral tissues, while there were no bacteria in tissues from ciprofloxacin-treated macaques. CONCLUSIONS Both doxycycline and ciprofloxacin were efficacious in treatment of pneumonic tularemia, although clearance of bacteria may be different between the 2 drugs.
Collapse
Affiliation(s)
- Mark S Williams
- Office of Biodefense Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
8
|
Maurin M, Pondérand L, Hennebique A, Pelloux I, Boisset S, Caspar Y. Tularemia treatment: experimental and clinical data. Front Microbiol 2024; 14:1348323. [PMID: 38298538 PMCID: PMC10827922 DOI: 10.3389/fmicb.2023.1348323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2023] [Accepted: 12/31/2023] [Indexed: 02/02/2024] Open
Abstract
Tularemia is a zoonosis caused by the Gram negative, facultative intracellular bacterium Francisella tularensis. This disease has multiple clinical presentations according to the route of infection, the virulence of the infecting bacterial strain, and the underlying medical condition of infected persons. Systemic infections (e.g., pneumonic and typhoidal form) and complications are rare but may be life threatening. Most people suffer from local infection (e.g., skin ulcer, conjunctivitis, or pharyngitis) with regional lymphadenopathy, which evolve to suppuration in about 30% of patients and a chronic course of infection. Current treatment recommendations have been established to manage acute infections in the context of a biological threat and do not consider the great variability of clinical situations. This review summarizes literature data on antibiotic efficacy against F. tularensis in vitro, in animal models, and in humans. Empirical treatment with beta-lactams, most macrolides, or anti-tuberculosis agents is usually ineffective. The aminoglycosides gentamicin and streptomycin remain the gold standard for severe infections, and the fluoroquinolones and doxycycline for infections of mild severity, although current data indicate the former are usually more effective. However, the antibiotic treatments reported in the literature are highly variable in their composition and duration depending on the clinical manifestations, the age and health status of the patient, the presence of complications, and the evolution of the disease. Many patients received several antibiotics in combination or successively. Whatever the antibiotic treatment administered, variable but high rates of treatment failures and relapses are still observed, especially in patients treated more then 2-3 weeks after disease onset. In these patients, surgical treatment is often necessary for cure, including drainage or removal of suppurative lymph nodes or other infectious foci. It is currently difficult to establish therapeutic recommendations, particularly due to lack of comparative randomized studies. However, we have attempted to summarize current knowledge through proposals for improving tularemia treatment which will have to be discussed by a group of experts. A major factor in improving the prognosis of patients with tularemia is the early administration of appropriate treatment, which requires better medical knowledge and diagnostic strategy of this disease.
Collapse
Affiliation(s)
- Max Maurin
- Centre National de Référence Francisella tularensis, CHU Grenoble Alpes, Grenoble, France
- Université Grenoble Alpes, Translational Innovation in Medicine and Complexity (TIMC), Centre National de la Recherche Scientifique (CNRS), Grenoble, France
| | - Léa Pondérand
- Centre National de Référence Francisella tularensis, CHU Grenoble Alpes, Grenoble, France
- Université Grenoble Alpes, Commissariat à l’énergie atomique (CEA), CNRS, Institut de Biologie Structurale (IBS), Grenoble, France
| | - Aurélie Hennebique
- Centre National de Référence Francisella tularensis, CHU Grenoble Alpes, Grenoble, France
- Université Grenoble Alpes, Translational Innovation in Medicine and Complexity (TIMC), Centre National de la Recherche Scientifique (CNRS), Grenoble, France
| | - Isabelle Pelloux
- Centre National de Référence Francisella tularensis, CHU Grenoble Alpes, Grenoble, France
| | - Sandrine Boisset
- Centre National de Référence Francisella tularensis, CHU Grenoble Alpes, Grenoble, France
- Université Grenoble Alpes, Commissariat à l’énergie atomique (CEA), CNRS, Institut de Biologie Structurale (IBS), Grenoble, France
| | - Yvan Caspar
- Centre National de Référence Francisella tularensis, CHU Grenoble Alpes, Grenoble, France
- Université Grenoble Alpes, Commissariat à l’énergie atomique (CEA), CNRS, Institut de Biologie Structurale (IBS), Grenoble, France
| |
Collapse
|
9
|
Sharma R, Patil RD, Singh B, Chakraborty S, Chandran D, Dhama K, Gopinath D, Jairath G, Rialch A, Mal G, Singh P, Chaicumpa W, Saikumar G. Tularemia - a re-emerging disease with growing concern. Vet Q 2023; 43:1-16. [PMID: 37916743 PMCID: PMC10732219 DOI: 10.1080/01652176.2023.2277753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Accepted: 10/25/2023] [Indexed: 11/03/2023] Open
Abstract
Tularemia caused by Gram-negative, coccobacillus bacterium, Francisella tularensis, is a highly infectious zoonotic disease. Human cases have been reported mainly from the United States, Nordic countries like Sweden and Finland, and some European and Asian countries. Naturally, the disease occurs in several vertebrates, particularly lagomorphs. Type A (subspecies tularensis) is more virulent and causes disease mainly in North America; type B (subspecies holarctica) is widespread, while subspecies mediasiatica is present in central Asia. F. tularensis is a possible bioweapon due to its lethality, low infectious dosage, and aerosol transmission. Small mammals like rabbits, hares, and muskrats are primary sources of human infections, but true reservoir of F. tularensis is unknown. Vector-borne tularemia primarily involves ticks and mosquitoes. The bacterial subspecies involved and mode of transmission determine the clinical picture. Early signs are flu-like illnesses that may evolve into different clinical forms of tularemia that may or may not include lymphadenopathy. Ulcero-glandular and glandular forms are acquired by arthropod bite or handling of infected animals, oculo-glandular form as a result of conjunctival infection, and oro-pharyngeal form by intake of contaminated food or water. Pulmonary form appears after inhalation of bacteria. Typhoidal form may occur after infection via different routes. Human-to-human transmission has not been known. Diagnosis can be achieved by serology, bacterial culture, and molecular methods. Treatment for tularemia typically entails use of quinolones, tetracyclines, or aminoglycosides. Preventive measures are necessary to avoid infection although difficult to implement. Research is underway for the development of effective live attenuated and subunit vaccines.
Collapse
Affiliation(s)
- Rinku Sharma
- Disease Investigation Laboratory, ICAR-Indian Veterinary Research Institute, Regional Station, Palampur, Himachal Pradesh, India
| | - Rajendra Damu Patil
- Department of Veterinary Pathology, DGCN College of Veterinary and Animal Sciences, CSK HPKV, Palampur, Himachal Pradesh, India
| | - Birbal Singh
- Disease Investigation Laboratory, ICAR-Indian Veterinary Research Institute, Regional Station, Palampur, Himachal Pradesh, India
| | - Sandip Chakraborty
- Department of Veterinary Microbiology, College of Veterinary Sciences and Animal Husbandry, R.K. Nagar, West Tripura, India
| | | | - Kuldeep Dhama
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| | - Devi Gopinath
- Disease Investigation Laboratory, ICAR-Indian Veterinary Research Institute, Regional Station, Palampur, Himachal Pradesh, India
| | - Gauri Jairath
- Disease Investigation Laboratory, ICAR-Indian Veterinary Research Institute, Regional Station, Palampur, Himachal Pradesh, India
| | - Ajayta Rialch
- Disease Investigation Laboratory, ICAR-Indian Veterinary Research Institute, Regional Station, Palampur, Himachal Pradesh, India
| | - Gorakh Mal
- Disease Investigation Laboratory, ICAR-Indian Veterinary Research Institute, Regional Station, Palampur, Himachal Pradesh, India
| | - Putan Singh
- Disease Investigation Laboratory, ICAR-Indian Veterinary Research Institute, Regional Station, Palampur, Himachal Pradesh, India
| | - Wanpen Chaicumpa
- Center of Research Excellence in Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - G. Saikumar
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India
| |
Collapse
|
10
|
Zhao M, Zhai Y, Zai X, Mao Y, Hu E, Wei Z, Li Y, Li K, Liu Y, Xu J, Yu R, Chen W. Comparative evaluation of protective immunity against Francisella tularensis induced by subunit or adenovirus-vectored vaccines. Front Cell Infect Microbiol 2023; 13:1195314. [PMID: 37305410 PMCID: PMC10248143 DOI: 10.3389/fcimb.2023.1195314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 05/16/2023] [Indexed: 06/13/2023] Open
Abstract
Tularemia is a highly contagious disease caused by infection with Francisella tularensis (Ft), a pathogenic intracellular gram-negative bacterium that infects a wide range of animals and causes severe disease and death in people, making it a public health concern. Vaccines are the most effective way to prevent tularemia. However, there are no Food and Drug Administration (FDA)-approved Ft vaccines thus far due to safety concerns. Herein, three membrane proteins of Ft, Tul4, OmpA, and FopA, and a molecular chaperone, DnaK, were identified as potential protective antigens using a multifactor protective antigen platform. Moreover, the recombinant DnaK, FopA, and Tul4 protein vaccines elicited a high level of IgG antibodies but did not protect against challenge. In contrast, protective immunity was elicited by a replication-defective human type 5 adenovirus (Ad5) encoding the Tul4, OmpA, FopA, and DnaK proteins (Ad5-Tul4, Ad5-OmpA, Ad5-FopA, and Ad5-DnaK) after a single immunization, and all Ad5-based vaccines stimulated a Th1-biased immune response. Moreover, intramuscular and intranasal vaccination with Ad5-Tul4 using the prime-boost strategy effectively eliminated Ft lung, spleen and liver colonization and provided nearly 80% protection against intranasal challenge with the Ft live vaccine strain (LVS). Only intramuscular, not intranasal vaccination, with Ad5-Tul4 protected mice from intraperitoneal challenge. This study provides a comprehensive comparison of protective immunity against Ft provided by subunit or adenovirus-vectored vaccines and suggests that mucosal vaccination with Ad5-Tul4 may yield desirable protective efficacy against mucosal infection, while intramuscular vaccination offers greater overall protection against intraperitoneal tularemia.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Rui Yu
- *Correspondence: Rui Yu, ; Wei Chen,
| | - Wei Chen
- *Correspondence: Rui Yu, ; Wei Chen,
| |
Collapse
|
11
|
Cantlay S, Kaftanic C, Horzempa J. PdpC, a secreted effector protein of the type six secretion system, is required for erythrocyte invasion by Francisella tularensis LVS. Front Cell Infect Microbiol 2022; 12:979693. [PMID: 36237421 PMCID: PMC9552824 DOI: 10.3389/fcimb.2022.979693] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Accepted: 09/02/2022] [Indexed: 12/01/2022] Open
Abstract
Francisella tularensis is a gram negative, intracellular pathogen that is the causative agent of the potentially fatal disease, tularemia. During infection, F. tularensis is engulfed by and replicates within host macrophages. Additionally, this bacterium has also been shown to invade human erythrocytes and, in both cases, the Type Six Secretion System (T6SS) is required for these host-pathogen interaction. One T6SS effector protein, PdpC, is important for macrophage infection, playing a role in phagolysosomal escape and intracellular replication. To determine if PdpC also plays a role in erythrocyte invasion, we constructed a pdpC-null mutant in the live vaccine strain, F. tularensis LVS. We show that PdpC is required for invasion of human and sheep erythrocytes during in vitro assays and that reintroduction of a copy of pdpC, in trans, rescues this phenotype. The interaction with human erythrocytes was further characterized using double-immunofluorescence microscopy to show that PdpC is required for attachment of F. tularensis LVS to erythrocytes as well as invasion. To learn more about the role of PdpC in erythrocyte invasion we generated a strain of F. tularensis LVS expressing pdpC-emgfp. PdpC-EmGFP localizes as discrete foci in a subset of F. tularensis LVS cells grown in broth culture and accumulates in erythrocytes during invasion assays. Our results are the first example of a secreted effector protein of the T6SS shown to be involved in erythrocyte invasion and indicate that PdpC is secreted into erythrocytes during invasion.
Collapse
Affiliation(s)
| | | | - Joseph Horzempa
- Department of Biological Sciences, West Liberty University, West Liberty, WV, United States
| |
Collapse
|
12
|
Fever and Ulcerative Skin Lesions in a Patient Referred for Altered Mental Status: Clinical and Microbiological Diagnosis of Ulceroglandular Tularemia. Trop Med Infect Dis 2022; 7:tropicalmed7090220. [PMID: 36136631 PMCID: PMC9504304 DOI: 10.3390/tropicalmed7090220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 08/29/2022] [Accepted: 08/30/2022] [Indexed: 12/04/2022] Open
Abstract
Background: Tularemia is a devastating disease that affects multiple organ systems and can have several different presentations. In its most frequent form—that of ulceroglandular tularemia—a detailed history and physical examination can enable a physician to make the diagnosis clinically, leading to the prompt initiation of the appropriate antibiotic treatment. Detailed Case Description: A 63-year-old man was brought by ambulance to the emergency department for an evaluation of an altered mental status noted by his psychiatrist at a telehealth appointment. A physical examination revealed a fever and two ulcerative lesions with a central eschar on his left leg (of which the patient was unaware) with ipsilateral tender inguinal lymphadenopathy. When asked, the patient recalled visiting Martha’s Vineyard and having removed ticks from his legs. Gentamicin was administered on the clinical suspicion of ulceroglandular tularemia. Blood and skin lesion cultures grew Gram-negative rods, which were confirmed to be Francisella tularensis on hospital day eight, and the patient fully recovered. Conclusion: This case highlights the importance of clinician perception of altered mental status as a key alarm sign, the necessity of a thorough physical exam independent of the chief compliant in the emergency department, and the essential role of pattern recognition by front-line providers for the appropriate management of uncommon but serious infections such as tularemia.
Collapse
|
13
|
Sullivan AP, Nicholson C, Bradbury-Squires DJ, King A, Daley P. Two cases of tularemia in hunters from rural Newfoundland. JOURNAL OF THE ASSOCIATION OF MEDICAL MICROBIOLOGY AND INFECTIOUS DISEASE CANADA = JOURNAL OFFICIEL DE L'ASSOCIATION POUR LA MICROBIOLOGIE MEDICALE ET L'INFECTIOLOGIE CANADA 2022; 7:135-139. [PMID: 36337354 PMCID: PMC9608108 DOI: 10.3138/jammi-2020-0015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2021] [Revised: 10/22/2021] [Accepted: 11/05/2021] [Indexed: 06/16/2023]
Abstract
BACKGROUND Tularemia is a rare zoonosis caused by Francisella tularensis, a small gram-negative intracellular coccobacillus. Transmission occurs through direct contact with small mammals such as hares and rabbits, exposure to ticks, or ingestion or inhalation of aerosolized particles. It is a highly variable disease with six subtypes based on clinical features. Tularemia is a very rare disease in Canada, with only 0.01 cases per 100,000 people reported in 2017. METHODS In this case report, we describe two cases of tularemia affecting hunters from rural Newfoundland and Labrador. RESULTS The first case describes a patient with glandular tularemia diagnosed with serology; the second describes a patient with typhoidal tularemia diagnosed on blood culture. Both patients recovered after treatment with gentamicin. DISCUSSION These cases highlight the importance of eliciting a careful social history from patients presenting with an unexplained febrile illness. Tularemia should be considered in the differential diagnosis of fever after hunting in rural areas.
Collapse
Affiliation(s)
- Andrew P Sullivan
- Discipline of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland
| | - Catherine Nicholson
- Discipline of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland
| | | | - Amy King
- Discipline of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland
| | - Peter Daley
- Discipline of Medicine, Memorial University of Newfoundland, St. John’s, Newfoundland
| |
Collapse
|
14
|
COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. J Microbiol 2022; 60:321-334. [PMID: 35157221 PMCID: PMC8853094 DOI: 10.1007/s12275-022-1621-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 12/30/2021] [Accepted: 12/31/2021] [Indexed: 12/11/2022]
Abstract
Severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) infection, which causes coronavirus disease 2019 (COVID-19), has led to many cases and deaths worldwide. Therefore, a number of vaccine candidates have been developed to control the COVID-19 pandemic. Of these, to date, 21 vaccines have received emergency approval for human use in at least one country. However, the recent global emergence of SARS-CoV-2 variants has compromised the efficacy of the currently available vaccines. To protect against these variants, the use of vaccines that modulate T cell-mediated immune responses or innate immune cell memory function, termed trained immunity, is needed. The major advantage of a vaccine that uses bacteria or viral systems for the delivery of COVID-19 antigens is the ability to induce both T cell-mediated and humoral immune responses. In addition, such vaccine systems can also exert off-target effects via the vector itself, mediated partly through trained immunity; compared to other vaccine platforms, suggesting that this approach can provide better protection against even vaccine escape variants. This review presents the current status of the development of COVID-19 vaccines based on recombinant viral and bacterial delivery systems. We also discuss the current status of the use of licensed live vaccines for other infections, including BCG, oral polio and MMR vaccines, to prevent COVID-19 infections.
Collapse
|
15
|
Assessment of Zoonotic Risk following Diagnosis of Canine Tularemia in a Veterinary Medical Teaching Hospital. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:ijerph19042011. [PMID: 35206199 PMCID: PMC8872237 DOI: 10.3390/ijerph19042011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Revised: 02/04/2022] [Accepted: 02/08/2022] [Indexed: 11/27/2022]
Abstract
Tularemia is a rare zoonotic disease found worldwide. The agent responsible for disease, Francisella tularensis, is one of the most highly infectious pathogens known, one that is capable of causing life-threatening illness with inhalation of <50 organisms. High infectivity explains concerns of its use in bioterrorism. This case describes a 4-year-old male neutered Australian shepherd presented for evaluation of hyporexia and fever. Physical examination revealed marked enlargement of the right superficial cervical lymph node. Tularemia lymphadenitis was diagnosed by lymph node aspiration cytology and culture. Public health officials were advised of the isolation of this zoonotic pathogen, and contact tracing was instituted. Seven individuals associated with the aspiration event were screened for tularemia and treated with prophylactic ciprofloxacin. All were negative, and none became sick. The dog was treated with doxycycline for 3 weeks, and clinical signs and physical examination abnormalities were resolved fully. The owner, a solid organ transplant recipient, was also screened for disease and received prophylactic doxycycline due to a history of shared exposure. The owner remained well throughout the course of his dog’s disease and has heightened awareness of potential zoonoses. This case highlights the importance of animals as a sentinel for human health threats and for coordination of human and veterinary care.
Collapse
|
16
|
Gor D, Wiseman K, Lesniak C, Liu E. A Rare Occurrence of Tularemia in New Jersey. Cureus 2021; 13:e18329. [PMID: 34725592 PMCID: PMC8553285 DOI: 10.7759/cureus.18329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/26/2021] [Indexed: 11/11/2022] Open
Abstract
Tularemia has been well described clinically in the United States since the early 1900s. Worldwide, the infection has manifested in a variety of forms through various vectors with geography and local prevalence often considered in the diagnostic work-up. We present a case of a 57-year-old patient who lived in an area with low tularemia infection rates and presented with fever and a tender, swollen elbow. Though initially diagnosed with cellulitis, she was eventually found to have tularemia after further interviewing and questioning, followed by successful treatment with doxycycline. A thorough history including exposures and daily activities should always be considered in an effort to rule out rare infections, even in areas of low disease prevalence.
Collapse
Affiliation(s)
- Dhairya Gor
- Internal Medicine, Jersey Shore University Medical Center, Neptune, USA
| | - Kyle Wiseman
- Internal Medicine, Jersey Shore University Medical Center, Neptune, USA
| | | | - Edward Liu
- Internal Medicine, Jersey Shore University Medical Center, Neptune, USA
| |
Collapse
|
17
|
Martinet P, Khatchatourian L, Saidani N, Fangous MS, Goulon D, Lesecq L, Le Gall F, Guerpillon B, Corre R, Bizien N, Talarmin JP. Hypermetabolic pulmonary lesions on FDG-PET/CT: Tularemia or neoplasia? Infect Dis Now 2021; 51:607-613. [PMID: 34242840 DOI: 10.1016/j.idnow.2021.06.307] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 06/28/2021] [Accepted: 06/30/2021] [Indexed: 11/25/2022]
Abstract
OBJECTIVES Pulmonary tularemia is a rare and little-known disease, whose clinical and radiological presentation can be confused with those of much more frequent pathologies, such as lung cancer or B-cell lymphoma (46,000 and 5,000 new cases respectively per year in France). Furthermore, PET/CT is a powerful tool for the diagnosis of malignancies or the exploration of fever of unknown origin. The objective of this study was to describe the characteristics of pulmonary tularemia and to determine whether its PET/CT aspect could help distinguish it from neoplasia. METHODS Retrospective observational study collecting all pulmonary tularemia cases for which a PET/CT was performed between 2016 and 2020. RESULTS Twenty-seven cases of pulmonary tularemia were analyzed. The sex ratio was 4.4, and the median age was 60 years. Clinical manifestations were mainly represented by fever (n=23), arthralgia (n=7) and cough (n=6). PET/CT revealed intensely hypermetabolic mediastinal adenopathies in all cases, associated with parenchymal (n=20) or pleural (n=6) lesions, suggesting neoplastic pathology in 15 patients. Cytopuncture or lymph node biopsy was performed in 16 patients, revealing non-specific adenitis (n=8), necrotic epithelio-gigantocellular granuloma (n=3), or were non-contributory (n=5). All patients reported significant environmental exposure. The outcome was favorable for all patients, spontaneously for 8 of them and after antibiotic therapy with either doxycycline or ciprofloxacin for the other 19. CONCLUSIONS Depending on the epidemiological setting, pulmonary tularemia may be considered an alternative diagnosis to lung cancer, lymphoma, or tuberculosis, in the presence of infectious symptoms and hypermetabolic pulmonary lesions and mediastinal lymphadenopathies on PET/CT.
Collapse
Affiliation(s)
- Pauline Martinet
- Department of Infectious Diseases, Centre Hospitalier de Cornouaille, 14, avenue Yves Thépot, 29000 Quimper, France
| | - Lydie Khatchatourian
- Department of Infectious Diseases, Centre Hospitalier de Cornouaille, 14, avenue Yves Thépot, 29000 Quimper, France
| | - Nadia Saidani
- Department of Infectious Diseases, Centre Hospitalier de Cornouaille, 14, avenue Yves Thépot, 29000 Quimper, France
| | - Marie-Sarah Fangous
- Department of Microbiology, Centre Hospitalier de Cornouaille, Quimper, France
| | - Dorothée Goulon
- Department of Nuclear Medicine, Centre Georges Charpak, Quimper, France
| | - Ludovic Lesecq
- Department of Infectious Diseases, Clinique Saint Michel, Quimper, France
| | - Florence Le Gall
- Department of Microbiology, Centre Hospitalier de Cornouaille, Quimper, France
| | - Brice Guerpillon
- Department of Infectious Diseases, Centre Hospitalier de Cornouaille, 14, avenue Yves Thépot, 29000 Quimper, France
| | - Romain Corre
- Department of Pulmonary Diseases, Centre Hospitalier de Cornouaille, Quimper, France
| | - Nicolas Bizien
- Department of Pulmonary Diseases, Centre Hospitalier de Cornouaille, Quimper, France
| | - Jean-Philippe Talarmin
- Department of Infectious Diseases, Centre Hospitalier de Cornouaille, 14, avenue Yves Thépot, 29000 Quimper, France.
| |
Collapse
|
18
|
Brunet CD, Hennebique A, Peyroux J, Pelloux I, Caspar Y, Maurin M. Presence of Francisella tularensis subsp. holarctica DNA in the Aquatic Environment in France. Microorganisms 2021; 9:microorganisms9071398. [PMID: 34203503 PMCID: PMC8306966 DOI: 10.3390/microorganisms9071398] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Revised: 06/24/2021] [Accepted: 06/25/2021] [Indexed: 01/08/2023] Open
Abstract
In 2018, the incidence of tularemia increased twofold in the west of France, with many pneumonic forms, suggesting environmental sources of infection. We investigated the presence of Francisellatularensis subsp. holarctica and other Francisella species DNA in the natural aquatic environment of this geographic area. Two sampling campaigns, in July 2019 and January 2020, allowed the collection of 87 water samples. Using a combination of real-time PCR assays, we tested the presence of either Francisella sp., F. tularensis/F. novicida, and F. tularensis subsp. holarctica, the latter being the only tularemia agent in Europe. Among 57 water samples of the first campaign, 15 (26.3%) were positive for Francisella sp., nine (15.8%) for F. tularensis and/or F. novicida, and four (7.0%) for F. tularensis subsp. holarctica. Ratios were 25/30 (83.3%), 24/30 (80.0%), and 4/30 (13.3%) for the second campaign. Among the thirty sites sampled during the two campaigns, nine were positive both times for Francisella sp., seven for F. tularensis and/or F. novicida, and one for F. tularensis subsp. holarctica. Altogether, our study reveals a high prevalence of Francisella sp. DNA (including the tularemia agent) in the studied aquatic environment. This aquatic environment could therefore participate in the endemicity of tularemia in the west of France.
Collapse
Affiliation(s)
- Camille D. Brunet
- Centre National de la Recherche Scientifique, Université Grenoble Alpes, TIMC, UMR5525, 38000 Grenoble, France; (C.D.B.); (A.H.); (J.P.); (Y.C.)
| | - Aurélie Hennebique
- Centre National de la Recherche Scientifique, Université Grenoble Alpes, TIMC, UMR5525, 38000 Grenoble, France; (C.D.B.); (A.H.); (J.P.); (Y.C.)
- Centre National de Référence des Francisella, Centre Hospitalier Universitaire Grenoble Alpes, 38000 Grenoble, France;
| | - Julien Peyroux
- Centre National de la Recherche Scientifique, Université Grenoble Alpes, TIMC, UMR5525, 38000 Grenoble, France; (C.D.B.); (A.H.); (J.P.); (Y.C.)
| | - Isabelle Pelloux
- Centre National de Référence des Francisella, Centre Hospitalier Universitaire Grenoble Alpes, 38000 Grenoble, France;
| | - Yvan Caspar
- Centre National de la Recherche Scientifique, Université Grenoble Alpes, TIMC, UMR5525, 38000 Grenoble, France; (C.D.B.); (A.H.); (J.P.); (Y.C.)
- Centre National de Référence des Francisella, Centre Hospitalier Universitaire Grenoble Alpes, 38000 Grenoble, France;
| | - Max Maurin
- Centre National de la Recherche Scientifique, Université Grenoble Alpes, TIMC, UMR5525, 38000 Grenoble, France; (C.D.B.); (A.H.); (J.P.); (Y.C.)
- Centre National de Référence des Francisella, Centre Hospitalier Universitaire Grenoble Alpes, 38000 Grenoble, France;
- Correspondence:
| |
Collapse
|
19
|
Deletion Mutants of Francisella Phagosomal Transporters FptA and FptF Are Highly Attenuated for Virulence and Are Protective Against Lethal Intranasal Francisella LVS Challenge in a Murine Model of Respiratory Tularemia. Pathogens 2021; 10:pathogens10070799. [PMID: 34202420 PMCID: PMC8308642 DOI: 10.3390/pathogens10070799] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Revised: 06/09/2021] [Accepted: 06/17/2021] [Indexed: 11/17/2022] Open
Abstract
Francisella tularensis (Ft) is a Gram-negative, facultative intracellular bacterium that is a Tier 1 Select Agent of concern for biodefense for which there is no licensed vaccine. A subfamily of 9 Francisella phagosomal transporter (fpt) genes belonging to the Major Facilitator Superfamily of transporters was identified as critical to pathogenesis and potential targets for attenuation and vaccine development. We evaluated the attenuation and protective capacity of LVS derivatives with deletions of the fptA and fptF genes in the C57BL/6J mouse model of respiratory tularemia. LVSΔfptA and LVSΔfptF were highly attenuated with LD50 values of >20 times that of LVS when administered intranasally and conferred 100% protection against lethal challenge. Immune responses to the fpt mutant strains in mouse lungs on day 6 post-infection were substantially modified compared to LVS and were associated with reduced organ burdens and reduced pathology. The immune responses to LVSΔfptA and LVSΔfptF were characterized by decreased levels of IL-10 and IL-1β in the BALF versus LVS, and increased numbers of B cells, αβ and γδ T cells, NK cells, and DCs versus LVS. These results support a fundamental requirement for FptA and FptF in the pathogenesis of Ft and the modulation of the host immune response.
Collapse
|
20
|
Tick extracellular vesicles enable arthropod feeding and promote distinct outcomes of bacterial infection. Nat Commun 2021; 12:3696. [PMID: 34140472 PMCID: PMC8211691 DOI: 10.1038/s41467-021-23900-8] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2019] [Accepted: 05/24/2021] [Indexed: 02/06/2023] Open
Abstract
Extracellular vesicles are thought to facilitate pathogen transmission from arthropods to humans and other animals. Here, we reveal that pathogen spreading from arthropods to the mammalian host is multifaceted. Extracellular vesicles from Ixodes scapularis enable tick feeding and promote infection of the mildly virulent rickettsial agent Anaplasma phagocytophilum through the SNARE proteins Vamp33 and Synaptobrevin 2 and dendritic epidermal T cells. However, extracellular vesicles from the tick Dermacentor andersoni mitigate microbial spreading caused by the lethal pathogen Francisella tularensis. Collectively, we establish that tick extracellular vesicles foster distinct outcomes of bacterial infection and assist in vector feeding by acting on skin immunity. Thus, the biology of arthropods should be taken into consideration when developing strategies to control vector-borne diseases.
Collapse
|
21
|
Identification of an Attenuated Substrain of Francisella tularensis SCHU S4 by Phenotypic and Genotypic Analyses. Pathogens 2021; 10:pathogens10060638. [PMID: 34067337 PMCID: PMC8224608 DOI: 10.3390/pathogens10060638] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 05/17/2021] [Accepted: 05/18/2021] [Indexed: 01/13/2023] Open
Abstract
Pneumonic tularemia is a highly debilitating and potentially fatal disease caused by inhalation of Francisella tularensis. Most of our current understanding of its pathogenesis is based on the highly virulent F. tularensis subsp. tularensis strain SCHU S4. However, multiple sources of SCHU S4 have been maintained and propagated independently over the years, potentially generating genetic variants with altered virulence. In this study, the virulence of four SCHU S4 stocks (NR-10492, NR-28534, NR-643 from BEI Resources and FTS-635 from Battelle Memorial Institute) along with another virulent subsp. tularensis strain, MA00-2987, were assessed in parallel. In the Fischer 344 rat model of pneumonic tularemia, NR-643 and FTS-635 were found to be highly attenuated compared to NR-10492, NR-28534, and MA00-2987. In the NZW rabbit model of pneumonic tularemia, NR-643 caused morbidity but not mortality even at a dose equivalent to 500x the LD50 for NR-10492. Genetic analyses revealed that NR-10492 and NR-28534 were identical to each other, and nearly identical to the reference SCHU S4 sequence. NR-643 and FTS-635 were identical to each other but were found to have nine regions of difference in the genomic sequence when compared to the published reference SCHU S4 sequence. Given the genetic differences and decreased virulence, NR-643/FTS-635 should be clearly designated as a separate SCHU S4 substrain and no longer utilized in efficacy studies to evaluate potential vaccines and therapeutics against tularemia.
Collapse
|
22
|
Frick OM, Livingston VA, Whitehouse CA, Norris SL, Alves DA, Facemire PR, Reed DS, Nalca A. The Natural History of Aerosolized Francisella tularensis Infection in Cynomolgus Macaques. Pathogens 2021; 10:597. [PMID: 34068262 PMCID: PMC8153158 DOI: 10.3390/pathogens10050597] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 04/26/2021] [Accepted: 05/07/2021] [Indexed: 11/16/2022] Open
Abstract
Tularemia is a severe, zoonotic infection caused by the Gram-negative bacterium Francisella tularensis. Inhalation results in a rapid, severe bacterial pneumonia and sepsis, which can be lethal. Because the cynomolgus macaque is the accepted nonhuman primate model for tularemia, we conducted a natural history study of pneumonic tularemia by exposing macaques to target inhaled doses of 50, 500, or 5000 colony forming units (CFU) of F. tularensis subsp. tularensis SCHU S4. Two animals within the 50 CFU group (calculated doses of 10 and 11 CFU) survived the challenge, while the remainder succumbed to infection. Exposure of cynomolgus macaques to aerosolized SCHU S4 resulted in fever, anorexia, increased white blood cell counts, lymphopenia, thrombocytopenia, increased liver enzymes, alterations in electrocardiogram (ECG), and pathological changes typical of infection with F. tularensis, regardless of the challenge dose. Blood pressure dropped during the febrile phase, particularly as temperature began to drop and macaques succumbed to the disease. ECG analysis indicated that in 33% of the macaques, heart rate was not elevated during the febrile phase (Faget's sign; pulse-temperature disassociation), which has been reported in a similar percentage of human cases. These results indicated that infection of cynomolgus macaques with aerosolized F. tularensis results in similar disease progression and outcome as seen in humans, and that cynomolgus macaques are a reliable animal model to test medical countermeasures against aerosolized F. tularensis.
Collapse
Affiliation(s)
- Ondraya M. Frick
- Veterinary Medicine Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD 21702, USA; (O.M.F.); (V.A.L.); (S.L.N.)
| | - Virginia A. Livingston
- Veterinary Medicine Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD 21702, USA; (O.M.F.); (V.A.L.); (S.L.N.)
- Naval Medical Research Center, Undersea Medicine Department, Silver Spring, MD 20910, USA
| | - Chris A. Whitehouse
- Molecular and Translational Sciences Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD 21702, USA;
- Office of Research, Center for Veterinary Medicine, U.S. Food and Drug Administration, Laurel, MD 20708, USA
| | - Sarah L. Norris
- Veterinary Medicine Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD 21702, USA; (O.M.F.); (V.A.L.); (S.L.N.)
| | - Derron A. Alves
- Pathology Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD 21702, USA; (D.A.A.); (P.R.F.)
- Veterinary Services and Public Health Sanitation Directorate, Army Public Health Center, Aberdeen Proving Ground, MD 21010, USA
| | - Paul R. Facemire
- Pathology Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD 21702, USA; (D.A.A.); (P.R.F.)
| | - Douglas S. Reed
- Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA 15261, USA;
| | - Aysegul Nalca
- Core Support Directorate, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD 21702, USA
| |
Collapse
|
23
|
Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development. Microorganisms 2021; 9:microorganisms9050973. [PMID: 33946283 PMCID: PMC8145380 DOI: 10.3390/microorganisms9050973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 04/19/2021] [Accepted: 04/21/2021] [Indexed: 11/17/2022] Open
Abstract
Francisella tularensis (Ft) is a Gram-negative, facultative intracellular coccobacillus that is the etiological agent of tularemia. Interestingly, the disease tularemia has variable clinical presentations that are dependent upon the route of infection with Ft. Two of the most likely routes of Ft infection include intranasal and intradermal, which result in pneumonic and ulceroglandular tularemia, respectively. While there are several differences between these two forms of tularemia, the most notable disparity is between mortality rates: the mortality rate following pneumonic tularemia is over ten times that of the ulceroglandular disease. Understanding the differences between intradermal and intranasal Ft infections is important not only for clinical diagnoses and treatment but also for the development of a safe and effective vaccine. However, the immune correlates of protection against Ft, especially within the context of infection by disparate routes, are not yet fully understood. Recent advances in different animal models have revealed new insights in the complex interplay of innate and adaptive immune responses, indicating dissimilar patterns in both responses following infection with Ft via different routes. Further investigation of these differences will be crucial to predicting disease outcomes and inducing protective immunity via vaccination or natural infection.
Collapse
|
24
|
McEntire CRS, Song KW, McInnis RP, Rhee JY, Young M, Williams E, Wibecan LL, Nolan N, Nagy AM, Gluckstein J, Mukerji SS, Mateen FJ. Neurologic Manifestations of the World Health Organization's List of Pandemic and Epidemic Diseases. Front Neurol 2021; 12:634827. [PMID: 33692745 PMCID: PMC7937722 DOI: 10.3389/fneur.2021.634827] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2020] [Accepted: 01/25/2021] [Indexed: 01/02/2023] Open
Abstract
The World Health Organization (WHO) monitors the spread of diseases globally and maintains a list of diseases with epidemic or pandemic potential. Currently listed diseases include Chikungunya, cholera, Crimean-Congo hemorrhagic fever, Ebola virus disease, Hendra virus infection, influenza, Lassa fever, Marburg virus disease, Neisseria meningitis, MERS-CoV, monkeypox, Nipah virus infection, novel coronavirus (COVID-19), plague, Rift Valley fever, SARS, smallpox, tularemia, yellow fever, and Zika virus disease. The associated pathogens are increasingly important on the global stage. The majority of these diseases have neurological manifestations. Those with less frequent neurological manifestations may also have important consequences. This is highlighted now in particular through the ongoing COVID-19 pandemic and reinforces that pathogens with the potential to spread rapidly and widely, in spite of concerted global efforts, may affect the nervous system. We searched the scientific literature, dating from 1934 to August 2020, to compile data on the cause, epidemiology, clinical presentation, neuroimaging features, and treatment of each of the diseases of epidemic or pandemic potential as viewed through a neurologist's lens. We included articles with an abstract or full text in English in this topical and scoping review. Diseases with epidemic and pandemic potential can be spread directly from human to human, animal to human, via mosquitoes or other insects, or via environmental contamination. Manifestations include central neurologic conditions (meningitis, encephalitis, intraparenchymal hemorrhage, seizures), peripheral and cranial nerve syndromes (sensory neuropathy, sensorineural hearing loss, ophthalmoplegia), post-infectious syndromes (acute inflammatory polyneuropathy), and congenital syndromes (fetal microcephaly), among others. Some diseases have not been well-characterized from a neurological standpoint, but all have at least scattered case reports of neurological features. Some of the diseases have curative treatments available while in other cases, supportive care remains the only management option. Regardless of the pathogen, prompt, and aggressive measures to control the spread of these agents are the most important factors in lowering the overall morbidity and mortality they can cause.
Collapse
Affiliation(s)
- Caleb R. S. McEntire
- Massachusetts General Hospital (MGH)-Brigham Neurology Residency Program, Boston, MA, United States
| | - Kun-Wei Song
- Massachusetts General Hospital (MGH)-Brigham Neurology Residency Program, Boston, MA, United States
| | - Robert P. McInnis
- Massachusetts General Hospital (MGH)-Brigham Neurology Residency Program, Boston, MA, United States
| | - John Y. Rhee
- Massachusetts General Hospital (MGH)-Brigham Neurology Residency Program, Boston, MA, United States
| | - Michael Young
- Massachusetts General Hospital (MGH)-Brigham Neurology Residency Program, Boston, MA, United States
| | - Erika Williams
- Massachusetts General Hospital (MGH)-Brigham Neurology Residency Program, Boston, MA, United States
| | - Leah L. Wibecan
- Massachusetts General Hospital (MGH)-Brigham Pediatric Neurology Residency Program, Boston, MA, United States
| | - Neal Nolan
- Massachusetts General Hospital (MGH)-Brigham Neurology Residency Program, Boston, MA, United States
| | - Amanda M. Nagy
- Massachusetts General Hospital (MGH)-Brigham Pediatric Neurology Residency Program, Boston, MA, United States
| | - Jeffrey Gluckstein
- Massachusetts General Hospital (MGH)-Brigham Neurology Residency Program, Boston, MA, United States
| | - Shibani S. Mukerji
- Department of Neurology, Massachusetts General Hospital, Boston, MA, United States
| | - Farrah J. Mateen
- Department of Neurology, Massachusetts General Hospital, Boston, MA, United States
| |
Collapse
|
25
|
Ahmad F, Farooq A, Ghani Khan MU, Shabbir MZ, Rabbani M, Hussain I. Identification of Most Relevant Features for Classification of Francisella tularensis using Machine Learning. Curr Bioinform 2021. [DOI: 10.2174/1574893615666200219113900] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Francisella tularensis is a stealth pathogen fatal for animals and humans.
Ease of its propagation, coupled with high capacity for ailment and death makes it a potential
candidate for biological weapon.
Objective:
Work related to the pathogen’s classification and factors affecting its prolonged
existence in soil is limited to statistical measures. Machine learning other than conventional
analysis methods may be applied to better predict epidemiological modeling for this soil-borne
pathogen.
Methods:
Feature-ranking algorithms namely; relief, correlation and oneR are used for soil
attribute ranking. Moreover, classification algorithms; SVM, random forest, naive bayes, logistic
regression and MLP are used for classification of the soil attribute dataset for Francisella
tularensis positive and negative soils.
Results:
Feature-ranking methods concluded that clay, nitrogen, organic matter, soluble salts, zinc,
silt and nickel are the most significant attributes while potassium, phosphorous, iron, calcium,
copper, chromium and sand are the least contributing risk factors for the persistence of the
pathogen. However, clay is the most significant and potassium is the least contributing attribute.
Data analysis suggests that feature-ranking using relief produced classification accuracy of 84.35%
for multilayer perceptron; 82.99% for linear regression; 80.27% for SVM and random forest; and
78.23% for naive bayes, which is better than other ranking methods. MLP outperforms other
classifiers by generating an accuracy of 84.35%, 82.99% and 81.63% for feature-ranking using
relief, correlation and oneR algorithms, respectively.
Conclusion:
These models can significantly improve accuracy and can minimize the risk of
incorrect classification. They further help in controlling epidemics and thereby minimizing the
socio-economic impact on the society.
Collapse
Affiliation(s)
- Fareed Ahmad
- Department of Computer Science and Engineering, Faculty of Electrical Engineering, University of Engineering and Technology, Lahore, Pakistan
| | - Amjad Farooq
- Department of Computer Science and Engineering, Faculty of Electrical Engineering, University of Engineering and Technology, Lahore, Pakistan
| | - Muhammad Usman Ghani Khan
- Department of Computer Science and Engineering, Faculty of Electrical Engineering, University of Engineering and Technology, Lahore, Pakistan
| | | | - Masood Rabbani
- Institute of Microbiology, University of Veterinary and Animal Sciences, Lahore, Pakistan
| | - Irshad Hussain
- Institute of Microbiology, University of Veterinary and Animal Sciences, Lahore, Pakistan
| |
Collapse
|
26
|
Darmon-Curti A, Darmon F, Edouard S, Hennebique A, Guimard T, Martin-Blondel G, Klopfenstein T, Talarmin JP, Raoult D, Maurin M, Fournier PE. Tularemia: A Case Series of Patients Diagnosed at the National Reference Center for Rickettsioses From 2008 to 2017. Open Forum Infect Dis 2020; 7:ofaa440. [PMID: 33209946 PMCID: PMC7651688 DOI: 10.1093/ofid/ofaa440] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Accepted: 09/17/2020] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND We describe the epidemiological, clinical, and prognostic aspects of 177 tularemia cases diagnosed at the National Reference Center for rickettsioses, coxiellosis, and bartonelloses between 2008 and 2017. METHODS All patients with a microbiological diagnosis of tularemia made in the laboratory were included. Clinical and epidemiological data were collected retrospectively from clinicians in charge of patients using a standardized questionnaire. Diagnostic methods used were indirect immunofluorescence serology, real-time polymerase chain reaction (PCR), and universal PCR targeting the 16S ribosomal ribonucleic acid gene. RESULTS The series included 54 females and 123 males (sex ratio, 2.28; mean age, 47.38 years). Eighty-nine (50.2%) were confirmed as having tularemia on the basis of a positive Francisella tularensis PCR or seroconversion, and 88 (49.8%) were considered as probable due to a single positive serum. The regions of France that were most affected included Pays de la Loire (22% of cases), Nouvelle Aquitaine (18.6% of cases), and Grand Est (12.4% of cases). Patients became infected mainly through contact with rodents or game (38 cases, 21.4%), through tick-bites (23 cases, 12.9%), or during outdoor leisure activities (37 cases, 20.9%). Glandular and ulceroglandular forms were the most frequent (109 cases, 61.5%). Two aortitis, an infectious endocarditis, a myocarditis, an osteoarticular infection, and a splenic hematoma were also diagnosed. Tularemia was discovered incidentally in 54.8% of cases. Seventy-eight patients were hospitalized, and no deaths were reported. CONCLUSIONS Our data suggest that in an endemic area and/or in certain epidemiological contexts, tularemia should be sought to allow an optimized antibiotic therapy and a faster recovery.
Collapse
Affiliation(s)
- Anne Darmon-Curti
- Aix Marseille University, Institut de Recherche pour le Developpement (IRD), MEPHI, Institut Hospitalo Universitaire (IHU)-Méditerranée Infection, Marseille, France
| | - François Darmon
- Laboratoire d'Informatique Gaspard-Monge (LIGM), Unité Mixte de Recherche (UMR) 8049, Ecole des Ponts ParisTech, UPE, Marne-la-Vallée, France
| | - Sophie Edouard
- Aix Marseille University, Institut de Recherche pour le Developpement (IRD), MEPHI, Institut Hospitalo Universitaire (IHU)-Méditerranée Infection, Marseille, France
| | - Aurélie Hennebique
- Centre National de Référence des Francisella, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
- Université Grenoble Alpes, Centre National de la Recherche Scientifique, TIMC-IMAG, Grenoble, France
| | - Thomas Guimard
- Infectious Diseases and Emergency Department, Centre Hospitalier de La Roche sur Yon, La Roche-sur-Yon, France
| | - Guillaume Martin-Blondel
- Service des Maladies Infectieuses et Tropicales, CHU de Toulouse, Toulouse, France
- UMR INSERM/CNRS 1043, Centre de Physiopathologie Toulouse Purpan, Toulouse, France
| | | | - Jean-Philippe Talarmin
- Internal Medicine and Infectious Diseases Department, Centre Hospitalier de Cornouaille, Quimper, France
| | - Didier Raoult
- Aix Marseille University, Institut de Recherche pour le Developpement (IRD), MEPHI, Institut Hospitalo Universitaire (IHU)-Méditerranée Infection, Marseille, France
- Centre National de Référence des Rickettsia, Coxiella et Bartonella, IHU-Méditerranée Infection, Marseille, France
| | - Max Maurin
- Centre National de Référence des Francisella, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
- Université Grenoble Alpes, Centre National de la Recherche Scientifique, TIMC-IMAG, Grenoble, France
| | - Pierre-Edouard Fournier
- Centre National de Référence des Rickettsia, Coxiella et Bartonella, IHU-Méditerranée Infection, Marseille, France
- Aix Marseille University, IRD, Service de Santé des Armées, VITROME, IHU-Méditerranée Infection, Marseille, France
| |
Collapse
|
27
|
Maurin M. Francisella tularensis, Tularemia and Serological Diagnosis. Front Cell Infect Microbiol 2020; 10:512090. [PMID: 33194778 PMCID: PMC7649319 DOI: 10.3389/fcimb.2020.512090] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Accepted: 09/29/2020] [Indexed: 11/13/2022] Open
Abstract
Tularemia is a zoonotic disease caused by the bacterium Francisella tularensis. The predominant sources, routes of infection, and clinical manifestations of human infections greatly vary according to the geographic area considered. Moreover, clinical suspicion of tularemia is often tricky because of the lack of specificity of the clinical manifestations. Because F. tularensis isolation is tedious and detection of its DNA usually requires removal of infected tissues, serological techniques are most often used for diagnostic confirmation. However, these techniques are varied and poorly standardized. The microagglutination test (MAT), the indirect immunofluorescence assay (IFA), and ELISA tests are currently the most frequently used techniques. These home-made and commercial tests are mainly used for tularemia diagnosis but also seroprevalence studies. ELISA tests detect specific antibodies within two weeks of disease evaluation, compared to 2-3 weeks for MAT and IFA. However, more false-positive results are usually reported with ELISA. The long-term persistence of anti-F. tularensis antibodies in patients with past tularemia infection hampers the diagnostic specificity of all these tests. Also, cross-reacting antibodies have been described (especially with Brucella and Yersinia species), although usually at a low level. The immunoblotting technique can highlight these serological cross-reactions. Tularemia remains an underdiagnosed disease in most endemic areas, and the clinical presentations of this disease are evolving. It is necessary to improve further speed and accuracy of tularemia diagnosis, as well as the standardization of diagnostic procedures.
Collapse
Affiliation(s)
- Max Maurin
- Centre National de Référence Francisella tularensis, Laboratoire de Bactériologie, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.,Laboratoire Techniques de l'Ingénierie Médicale et de la Complexité Informatique-Mathématiques et Applications (TIMC-IMAG), Université Grenoble Alpes, Centre National de la Recherche Scientifique (CNRS), Grenoble, France
| |
Collapse
|
28
|
Pillai SP, DePalma L, Prentice KW, Ramage JG, Chapman C, Sarwar J, Parameswaran N, Petersen J, Yockey B, Young J, Singh A, Pillai CA, Manickam G, Thirunavkkarasu N, Avila JR, Sharma S, Morse SA, Venkateswaran K, Anderson K, Hodge DR. Comprehensive Laboratory Evaluation of a Specific Lateral Flow Assay for the Presumptive Identification of Francisella tularensis in Suspicious White Powders and Aerosol Samples. Health Secur 2020; 18:83-95. [PMID: 32324068 PMCID: PMC7194312 DOI: 10.1089/hs.2019.0151] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
We conducted a comprehensive, multi-phase laboratory evaluation of the Tularemia BioThreat Alert® (BTA) test, a lateral flow assay (LFA) for the rapid detection of Francisella tularensis. The study, conducted at 2 sites, evaluated the limit of detection (LOD) of this assay using the virulent SchuS4 strain and the avirulent LVS strain of F. tularensis. In 6-phase evaluation (linear dynamic range and reproducibility, inclusivity, near-neighbor, environmental background, white powder, and environmental filter extract), 13 diverse strains of F. tularensis, 8 Francisella near neighbors, 61 environmental background organisms, 26 white powders, and a pooled aerosol extract were tested. In the 937 tests performed, the Tularemia BTA demonstrated an LOD of 107 to 108 cfu/mL, with a sensitivity of 100.00%, specificity of 98.08%, and accuracy of 98.84%. These performance data are important for accurate interpretation of qualitative results arising from screening suspicious white powders in the field.
Collapse
Affiliation(s)
- Segaran P Pillai
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Lindsay DePalma
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Kristin W Prentice
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Jason G Ramage
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Carol Chapman
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Jawad Sarwar
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Nishanth Parameswaran
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Jeannine Petersen
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Brook Yockey
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - John Young
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Ajay Singh
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Christine A Pillai
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Gowri Manickam
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Nagarajan Thirunavkkarasu
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Julie R Avila
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Shashi Sharma
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Stephen A Morse
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Kodumudi Venkateswaran
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - Kevin Anderson
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| | - David R Hodge
- Segaran P. Pillai, PhD, is Director, Office of Laboratory Science and Safety, FDA Office of the Commissioner, Silver Spring, MD. Lindsay DePalma, MS, is a Staff Life Scientist, Booz Allen Hamilton, McLean, VA. Kristin W. Prentice, MS, is an Associate, Booz Allen Hamilton, Rockville, MD. Jason G. Ramage, MS, MBA, PMP, is Assistant Vice Chancellor for Research and Innovation and Director of Research Compliance, University of Arkansas, Fayetteville, AR. Carol Chapman, MS, is a Microbiologist, Geneva Foundation, Contractor Support to the Naval Medical Research Center, Silver Spring, MD. Jawad Sarwar, MS, is a Senior Research Scientist, and Nishanth Parameswaran is a Research Scientist; both at Omni Array Biotechnology, Rockville, MD. Jeannine Petersen, PhD, Brook Yockey, and John Young are Microbiologists; all with DHHS/CDC/OID/NCEZID/DVBD/BDB, Fort Collins, CO. Ajay Singh, PhD, is a Research Scientist, Laulima Government Solutions, Contractor Support to USAMRICD, Neurobiological Toxicology Branch, Analytical Toxicology Division, Aberdeen Proving Ground, MD. Christine A. Pillai and Gowri Manickam, PhD, are ORISE Fellow Research Scientists; Nagarajan Thirunavvukarasu, PhD, is an ORISE Fellow; and Shashi K. Sharma, PhD, is a Research Microbiologist; all at the FDA Center for Food Safety and Applied Nutrition, Molecular Methods Development Branch, Division of Microbiology, Office of Regulatory Science, College Park, MD. Julie R. Avila, MS, is a Scientific Associate, Lawrence Livermore National Laboratory, Biosciences and Biotechnology Division, Livermore, CA. Stephen A. Morse, MSPH, PhD, is a Senior Advisor, CDC Division of Select Agents and Toxins, and is currently with IHRC, Inc., Atlanta, GA. Kodumudi Venkateswaran, PhD, is Chief Scientist, Tetracore, Inc., Rockville, MD. Kevin Anderson, PhD, and David R. Hodge, PhD, are Program Managers, Science and Technology Directorate, US Department of Homeland Security, Washington, DC
| |
Collapse
|
29
|
Kravdal A, Stubhaug ØO, Wågø AG, Steien Sætereng M, Amundsen D, Piekuviene R, Kristiansen A. Pulmonary tularaemia: a differential diagnosis to lung cancer. ERJ Open Res 2020; 6:00093-2019. [PMID: 32613015 PMCID: PMC7322898 DOI: 10.1183/23120541.00093-2019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Accepted: 03/24/2020] [Indexed: 11/05/2022] Open
Abstract
Background Pulmonary manifestations of tularaemia are reported to be infrequent in previous publications. During 2016, we noticed an increase in the number of hospitalised patients with pulmonary tularaemia in Eastern Norway. We aimed to investigate primary pulmonary tularaemia in Eastern Norway in terms of symptoms, radiological and microbiological findings, incidence and risk exposure. Methods A retrospective analysis of consecutive primary pulmonary tularaemia cases from 2016 until 2018 was conducted. Results From 1 September, 2016 until 31 December, 2018, 22 patients were diagnosed with primary pulmonary tularaemia at Innlandet Hospital Trust, representing 48% of all reported tularaemia cases in the region. A peak annual incidence of 3.4 in 100 000 was found in 2017. All 22 patients lived in, or had recently visited, rural areas. Eighteen patients reported risk exposure for tularaemia, such as wood chopping, outdoor activities and farming prior to symptom onset. All patients experienced fever, and 19 patients had respiratory symptoms. Ten patients were in spontaneous recovery at diagnosis. All patients had a chest computed tomography scan. Overall, 19 patients had pulmonary lesions and 18 had enlarged intrathoracic lymph nodes. The computed tomography images were described as suspicious of malignancy in 17 patients. Conclusion Pulmonary manifestations in tularaemia occurred more frequently in our region than expected from previous reports. Although all patients had symptoms consistent with infection, the majority were primarily investigated considering lung cancer due to the radiology report. In endemic areas, pulmonary tularaemia may be an important differential diagnosis to lung cancer. Pulmonary tularaemia is possibly more frequent than previously reported. Due to similar radiological findings, pulmonary tularaemia may be an important differential diagnosis to lung cancer in endemic areas.https://bit.ly/2RcEPfN
Collapse
Affiliation(s)
- Astrid Kravdal
- Dept of Medicine, Innlandet Hospital Trust, Gjøvik, Norway
| | | | - Anne Grete Wågø
- Dept of Microbiology, St Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
| | | | - Dag Amundsen
- Dept of Medicine, Innlandet Hospital Trust, Lillehammer, Norway
| | | | | |
Collapse
|
30
|
Siebert C, Villers C, Pavlou G, Touquet B, Yakandawala N, Tardieux I, Renesto P. Francisella novicida and F. philomiragia biofilm features conditionning fitness in spring water and in presence of antibiotics. PLoS One 2020; 15:e0228591. [PMID: 32023304 PMCID: PMC7001994 DOI: 10.1371/journal.pone.0228591] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Accepted: 01/17/2020] [Indexed: 02/07/2023] Open
Abstract
Biofilms are currently considered as a predominant lifestyle of many bacteria in nature. While they promote survival of microbes, biofilms also potentially increase the threats to animal and public health in case of pathogenic species. They not only facilitate bacteria transmission and persistence, but also promote spreading of antibiotic resistance leading to chronic infections. In the case of Francisella tularensis, the causative agent of tularemia, biofilms have remained largely enigmatic. Here, applying live and static confocal microscopy, we report growth and ultrastructural organization of the biofilms formed in vitro by these microorganisms over the early transition from coccobacillary into coccoid shape during biofilm assembly. Using selective dispersing agents, we provided evidence for extracellular DNA (eDNA) being a major and conserved structural component of mature biofilms formed by both F. subsp. novicida and a human clinical isolate of F. philomiragia. We also observed a higher physical robustness of F. novicida biofilm as compared to F. philomiragia one, a feature likely promoted by specific polysaccharides. Further, F. novicida biofilms resisted significantly better to ciprofloxacin than their planktonic counterparts. Importantly, when grown in biofilms, both Francisella species survived longer in cold water as compared to free-living bacteria, a trait possibly associated with a gain in fitness in the natural aquatic environment. Overall, this study provides information on survival of Francisella when embedded with biofilms that should improve both the future management of biofilm-related infections and the design of effective strategies to tackle down the problematic issue of bacteria persistence in aquatic ecosystems.
Collapse
Affiliation(s)
| | - Corinne Villers
- TIMC-IMAG UMR 5525-UGA CNRS, Grenoble Cedex 9, France.,Université de Caen Normandie, EA4655 U2RM, Caen, France
| | - Georgios Pavlou
- Institute for Advanced Biosciences (IAB), Team Membrane Dynamics of Parasite-Host Cell Interactions, CNRS UMR 5309, INSERM U1209, Université Grenoble Alpes, Grenoble, France
| | - Bastien Touquet
- Institute for Advanced Biosciences (IAB), Team Membrane Dynamics of Parasite-Host Cell Interactions, CNRS UMR 5309, INSERM U1209, Université Grenoble Alpes, Grenoble, France
| | | | - Isabelle Tardieux
- Institute for Advanced Biosciences (IAB), Team Membrane Dynamics of Parasite-Host Cell Interactions, CNRS UMR 5309, INSERM U1209, Université Grenoble Alpes, Grenoble, France
| | | |
Collapse
|
31
|
Abstract
Deliberate dissemination of a biological agent via several different routes presents the latest challenge to global public health security. Novel pathogens and transmission methods can easily be exploited to cause disease outbreaks. Advancements in molecular biology that make it possible to genetically modify, edit, or disrupt the genome of pathogens increase the disease risk of an accidental or intentional release of pathogens with pandemic potential. The occurrence of a disease at more than an endemic level may stimulate an investigation to determine the source of the disease, who has the disease, when it occurred, and how it spreads. When intentional release of pathogens is suspected, investigators have the additional task of attributing the outbreak not only to a pathogen but also to a human source. The deliberate nature of such dissemination may be obvious. However, some forms of bioterrorism may be more covert, requiring molecular methods to uncover. The field of microbial forensics emerged following the anthrax attack in the United States in 2001 to extend epidemiologic principles to aid in the investigation of bioterrorism incidents. Microbial forensics combines epidemiology with genomic and microbiologic methods, to identify, characterize, and ascribe the cause of an incident resulting from the intentional or unintentional release of a harmful pathogen. Unlike routine epidemiologic investigations, microbial forensic investigations are undertaken when there is a potential crime due to the release of a pathogen with disease-causing potential. The investigation is conducted to attribute cause to a source based on indisputable evidence and is used to support criminal charges against the perpetrator(s). However, because bioterrorism may be unannounced, the initial investigation will start the same as to any public health incident of concern. This chapter discusses how epidemiology integrated with laboratory science can be used to identify the source of diseases caused by microorganisms or toxins—especially for attribution purposes.
Collapse
|
32
|
Williams MS, Baker MR, Guina T, Hewitt JA, Lanning L, Hill H, May JM, Fogtman B, Pittman PR. Retrospective Analysis of Pneumonic Tularemia in Operation Whitecoat Human Subjects: Disease Progression and Tetracycline Efficacy. Front Med (Lausanne) 2019; 6:229. [PMID: 31696118 PMCID: PMC6818494 DOI: 10.3389/fmed.2019.00229] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Accepted: 10/03/2019] [Indexed: 11/26/2022] Open
Abstract
Francisella tularensis is a highly infectious Gram-negative bacterium that is the etiologic agent of tularemia in animals and humans. The incidence of tularemia is very low with a lack of comprehensive data that describe disease in humans due to difficulty in understanding time and routes of exposure. Under the title Operation Whitecoat, researchers at Ft. Detrick, MD conducted 40 clinical studies of tularemia from 1958 to 1968. In these studies, one of the objectives was to evaluate candidate countermeasures for treatment or prophylaxis of disease after exposure to Francisella tularensis strain Schu S4 by inhalation. These studies were reviewed retrospectively to delineate the early signs and symptoms or natural history of pneumonic tularemia and examine the efficacy of tetracycline in controlled human clinical studies. Using vital signs, onset of fever was objectively defined and calculated for each subject, while Adverse Events reported after exposure were also used to define the timing of disease onset and symptoms of early disease. There was a dose response relationship between time to fever onset and exposed dose at 200 cfu (172.8 h), 700 cfu (163.2 h), 2,500 cfu (105.3 h), and 25,000 cfu (75.5 h). Onset of fever was typically the earliest sign of disease at all doses but was often accompanied by symptoms such as headache, myalgia, chest pain, and nausea, irrespective of dose except at 200 cfu where only 50% of subjects exhibited fever onset or symptoms. Examining the efficacy of different treatment regimens of tetracycline, ineffective treatments were indicated by relapse of disease (fever and Adverse Events) after cessation of antibiotic treatment. Stratification of the data suggested that treatment for <14 days or doses <2g/day was associated with increased percentage of subjects with relapse of disease symptoms. Although these types of human challenge studies would not be ethically possible now, the climate post-World War II supported human testing under rigorous conditions with informed consent. Thus, going back and analyzing these unique clinical human challenge studies has helped describe the course of infection and disease induced by a biothreat pathogen and possible countermeasures for treatment under controlled conditions.
Collapse
Affiliation(s)
- Mark S Williams
- Office of Biodefense Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Marianne R Baker
- Office of Biodefense Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Tina Guina
- Office of Biodefense Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Judith A Hewitt
- Office of Biodefense Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Lynda Lanning
- Office of Regulatory Affairs, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | | | | | - Beverly Fogtman
- Department of Clinical Research, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, United States
| | - Phillip R Pittman
- Department of Clinical Research, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, United States
| |
Collapse
|
33
|
Contributions of TolC Orthologs to Francisella tularensis Schu S4 Multidrug Resistance, Modulation of Host Cell Responses, and Virulence. Infect Immun 2019; 87:IAI.00823-18. [PMID: 30670554 DOI: 10.1128/iai.00823-18] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Accepted: 01/14/2019] [Indexed: 02/06/2023] Open
Abstract
Francisella tularensis is a Gram-negative, facultative intracellular pathogen and the causative agent of tularemia. Previous studies with the attenuated live vaccine strain (LVS) identified a role for the outer membrane protein TolC in modulation of host cell responses during infection and virulence in the mouse model of tularemia. TolC is an integral part of efflux pumps that export small molecules and type I secretion systems that export a range of bacterial virulence factors. In this study, we analyzed TolC and its two orthologs, FtlC and SilC, present in the fully virulent F. tularensis Schu S4 strain for their contributions to multidrug efflux, suppression of innate immune responses, and virulence. We found that each TolC ortholog participated in multidrug efflux, with overlapping substrate specificities for TolC and FtlC and a distinct substrate profile for SilC. In contrast to their shared roles in drug efflux, only TolC functioned in the modulation of macrophage apoptotic and proinflammatory responses to Schu S4 infection, consistent with a role in virulence factor delivery to host cells. In agreement with previous results with the LVS, the Schu S4 ΔtolC mutant was highly attenuated for virulence in mice by both the intranasal and intradermal routes of infection. Unexpectedly, FtlC was also critical for Schu S4 virulence, but only by the intradermal route. Our data demonstrate a conserved and critical role for TolC in modulation of host immune responses and Francisella virulence and also highlight strain- and route-dependent differences in the pathogenesis of tularemia.
Collapse
|
34
|
Serrano I, Gomes D, Ramilo D, Rebelo MT, da Fonseca IP, Moreira A, Oliveira M. An Overview of Zoonotic Disease Outbreaks and its Forensic Management Over Time. J Forensic Sci 2019; 64:1304-1311. [PMID: 30801721 DOI: 10.1111/1556-4029.14034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Revised: 01/31/2019] [Accepted: 02/01/2019] [Indexed: 12/20/2022]
Abstract
Most emerging or re-emerging infections are vector-borne or zoonotic and can be disseminated worldwide by infected humans or animals. They are a major public health problem and cause a great impact on economy. Zoonotic outbreaks began to be characterized in the 90s, after the creation of Europol and the FBI. Such investigations are carried by forensic pathologists and other specialists to determine whether an outbreak is natural or deliberate. This review will discuss ten zoonotic outbreaks nonrelated to wars focusing on forensic management. In conclusion, some points should be highlighted in the management of a zoonotic outbreak: (i) its diagnosis and detection by forensic pathologists and the coordination of efforts between other specialists are key factors; (ii) communication guidelines and an efficient healthcare system are crucial for any emergency response; (iii) biosafety of all specialists involved must be guaranteed.
Collapse
Affiliation(s)
| | | | - David Ramilo
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Avenida da Universidade Técnica, 1300-477, Lisbon, Portugal
| | - Maria Teresa Rebelo
- Faculdade de Ciências da Universidade de Lisboa e Centro de Estudos do Ambiente e do Mar (CESAM), Campo Grande, 1749-016, Lisboa, Portugal
| | - Isabel Pereira da Fonseca
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Avenida da Universidade Técnica, 1300-477, Lisbon, Portugal
| | - Anabela Moreira
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Avenida da Universidade Técnica, 1300-477, Lisbon, Portugal
| | - Manuela Oliveira
- CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Avenida da Universidade Técnica, 1300-477, Lisbon, Portugal
| |
Collapse
|
35
|
Quillin KP, Fornwalt BE, Potesta EL, Nguyen CT. Oropharyngeal Tularemia: A Case of Ulcerative Pharyngitis and Necrotizing Pyogranulomatous Lymphadenitis. OTO Open 2019; 3:2473974X19833999. [PMID: 31236538 PMCID: PMC6572912 DOI: 10.1177/2473974x19833999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2018] [Revised: 12/14/2018] [Accepted: 02/06/2019] [Indexed: 11/22/2022] Open
Affiliation(s)
- Kyle P. Quillin
- Department of Otolaryngology, Bon Secours Mercy Health—St. Elizabeth Boardman Hospital, Boardman, Ohio, USA
| | - Brandon E. Fornwalt
- Department of Otolaryngology, Bon Secours Mercy Health—St. Elizabeth Boardman Hospital, Boardman, Ohio, USA
| | - Eugene L. Potesta
- Department of Otolaryngology, Bon Secours Mercy Health—St. Elizabeth Boardman Hospital, Boardman, Ohio, USA
| | - Cang T. Nguyen
- Department of Otolaryngology, Bon Secours Mercy Health—St. Elizabeth Boardman Hospital, Boardman, Ohio, USA
| |
Collapse
|
36
|
Hennebique A, Boisset S, Maurin M. Tularemia as a waterborne disease: a review. Emerg Microbes Infect 2019; 8:1027-1042. [PMID: 31287787 PMCID: PMC6691783 DOI: 10.1080/22221751.2019.1638734] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 06/27/2019] [Indexed: 12/20/2022]
Abstract
Francisella tularensis is a Gram-negative, intracellular bacterium causing the zoonosis tularemia. This highly infectious microorganism is considered a potential biological threat agent. Humans are usually infected through direct contact with the animal reservoir and tick bites. However, tularemia cases also occur after contact with a contaminated hydro-telluric environment. Water-borne tularemia outbreaks and sporadic cases have occurred worldwide in the last decades, with specific clinical and epidemiological traits. These infections represent a major public health and military challenge. Human contaminations have occurred through consumption or use of F. tularensis-contaminated water, and various aquatic activities such as swimming, canyoning and fishing. In addition, in Sweden and Finland, mosquitoes are primary vectors of tularemia due to infection of mosquito larvae in contaminated aquatic environments. The mechanisms of F. tularensis survival in water may include the formation of biofilms, interactions with free-living amoebae, and the transition to a 'viable but nonculturable' state, but the relative contribution of these possible mechanisms remains unknown. Many new aquatic species of Francisella have been characterized in recent years. F. tularensis likely shares with these species an ability of long-term survival in the aquatic environment, which has to be considered in terms of tularemia surveillance and control.
Collapse
Affiliation(s)
- Aurélie Hennebique
- Centre National de Référence des Francisella, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
- Université Grenoble Alpes, Centre National de la Recherche Scientifique, TIMC-IMAG, Grenoble, France
| | - Sandrine Boisset
- Centre National de Référence des Francisella, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
- Université Grenoble Alpes, Centre National de la Recherche Scientifique, TIMC-IMAG, Grenoble, France
| | - Max Maurin
- Centre National de Référence des Francisella, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
- Université Grenoble Alpes, Centre National de la Recherche Scientifique, TIMC-IMAG, Grenoble, France
| |
Collapse
|
37
|
Harrist A, Cherry C, Kwit N, Bryan K, Pappert R, Petersen J, Buttke D, Wong D, Nelson C. Francisella tularensis Exposure Among National Park Service Employees During an Epizootic: Devils Tower National Monument, Wyoming, 2015. Vector Borne Zoonotic Dis 2018; 19:316-322. [PMID: 30508402 DOI: 10.1089/vbz.2018.2360] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Introduction: Tularemia is a zoonotic infection caused by the highly infectious bacterium Francisella tularensis. Persons having outdoor professions are more likely than others to be exposed to F. tularensis through increased contact with arthropods, infected animals, and contaminated aerosols. Materials and Methods: After a tularemia epizootic during July and August 2015 at Devils Tower National Monument and an associated tularemia infection in a park employee, we assessed seroprevalence of F. tularensis antibodies, risk factors for F. tularensis seropositivity, and use of protective measures among park employees. Results: Seroprevalence among participating employees was 13% (3/23). Seropositive employees reported multiple risk factors for F. tularensis exposure through both job-related and recreational activities. Activities reported by more seropositive than seronegative employees included using a power blower (67% vs. 5%, p = 0.03), collecting animal carcasses (100% vs. 30%, p = 0.047), and hunting prairie dogs recreationally (67% vs. 5%, p = 0.03). Seropositive employees reported exposure to more ticks (median 30, range 25-35) than seronegative employees (median 6, range 0-25, p = 0.001). Most employees used protective measures (e.g., insect repellent) inconsistently but increased use after receiving educational materials. Conclusions: Educating and enabling at-risk employees to use protective measures consistently, both at work and during recreational activities, can reduce exposure during epizootics.
Collapse
Affiliation(s)
- Alexia Harrist
- 1 Epidemic Intelligence Service Program, Division of Scientific Education and Professional Development, Centers for Disease Control and Prevention, Atlanta, Georgia.,2 Public Health Division, Wyoming Department of Health, Cheyenne, Wyoming
| | - Cara Cherry
- 1 Epidemic Intelligence Service Program, Division of Scientific Education and Professional Development, Centers for Disease Control and Prevention, Atlanta, Georgia.,3 National Park Service, Fort Collins, Colorado
| | - Natalie Kwit
- 1 Epidemic Intelligence Service Program, Division of Scientific Education and Professional Development, Centers for Disease Control and Prevention, Atlanta, Georgia.,4 Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado
| | - Katie Bryan
- 2 Public Health Division, Wyoming Department of Health, Cheyenne, Wyoming
| | - Ryan Pappert
- 4 Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado
| | - Jeannine Petersen
- 4 Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado
| | | | - David Wong
- 3 National Park Service, Fort Collins, Colorado
| | - Christina Nelson
- 4 Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado
| |
Collapse
|
38
|
O’Malley KJ, Bowling JL, Stinson E, Cole KS, Mann BJ, Namjoshi P, Hazlett KRO, Barry EM, Reed DS. Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis. PLoS One 2018; 13:e0205928. [PMID: 30346998 PMCID: PMC6197691 DOI: 10.1371/journal.pone.0205928] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2018] [Accepted: 10/03/2018] [Indexed: 12/15/2022] Open
Abstract
Tularemia, also known as rabbit fever, is a severe zoonotic disease in humans caused by the gram-negative bacterium Francisella tularensis (Ft). While there have been a number of attempts to develop a vaccine for Ft, few candidates have advanced beyond experiments in inbred mice. We report here that a prime-boost strategy with aerosol delivery of recombinant live attenuated candidate Ft S4ΔaroD offers significant protection (83% survival) in an outbred animal model, New Zealand White rabbits, against aerosol challenge with 248 cfu (11 LD50) of virulent type A Ft SCHU S4. Surviving rabbits given two doses of the attenuated strains by aerosol did not exhibit substantial post-challenge fevers, changes in erythrocyte sedimentation rate or in complete blood counts. At a higher challenge dose (3,186 cfu; 139 LD50), protection was still good with 66% of S4ΔaroD-vaccinated rabbits surviving while 50% of S4ΔguaBA vaccinated rabbits also survived challenge. Pre-challenge plasma IgG titers against Ft SCHU S4 corresponded with survival time after challenge. Western blot analysis found that plasma antibody shifted from predominantly targeting Ft O-antigen after the prime vaccination to other antigens after the boost. These results demonstrate the superior protection conferred by a live attenuated derivative of virulent F. tularensis, particularly when given in an aerosol prime-boost regimen.
Collapse
Affiliation(s)
- Katherine J. O’Malley
- Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States of America
| | - Jennifer L. Bowling
- Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States of America
| | - Elizabeth Stinson
- Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States of America
| | - Kelly S. Cole
- Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States of America
| | - Barbara J. Mann
- Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, United States of America
| | - Prachi Namjoshi
- Department for Immunology & Microbial Diseases, Albany Medical College, Albany, NY, United States of America
| | - Karsten R. O. Hazlett
- Department for Immunology & Microbial Diseases, Albany Medical College, Albany, NY, United States of America
| | - Eileen M. Barry
- Center for Vaccine Development, University of Maryland Baltimore, Baltimore, MD, United States of America
| | - Douglas S. Reed
- Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States of America
- * E-mail:
| |
Collapse
|
39
|
McClellan G, Coleman M, Crary D, Thurman A, Thran B. Human Dose-Response Data for Francisella tularensis and a Dose- and Time-Dependent Mathematical Model of Early-Phase Fever Associated with Tularemia After Inhalation Exposure. RISK ANALYSIS : AN OFFICIAL PUBLICATION OF THE SOCIETY FOR RISK ANALYSIS 2018; 38:1685-1700. [PMID: 29694682 DOI: 10.1111/risa.12995] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Revised: 11/19/2017] [Accepted: 11/22/2017] [Indexed: 06/08/2023]
Abstract
Military health risk assessors, medical planners, operational planners, and defense system developers require knowledge of human responses to doses of biothreat agents to support force health protection and chemical, biological, radiological, nuclear (CBRN) defense missions. This article reviews extensive data from 118 human volunteers administered aerosols of the bacterial agent Francisella tularensis, strain Schu S4, which causes tularemia. The data set includes incidence of early-phase febrile illness following administration of well-characterized inhaled doses of F. tularensis. Supplemental data on human body temperature profiles over time available from de-identified case reports is also presented. A unified, logically consistent model of early-phase febrile illness is described as a lognormal dose-response function for febrile illness linked with a stochastic time profile of fever. Three parameters are estimated from the human data to describe the time profile: incubation period or onset time for fever; rise time of fever; and near-maximum body temperature. Inhaled dose-dependence and variability are characterized for each of the three parameters. These parameters enable a stochastic model for the response of an exposed population through incorporation of individual-by-individual variability by drawing random samples from the statistical distributions of these three parameters for each individual. This model provides risk assessors and medical decisionmakers reliable representations of the predicted health impacts of early-phase febrile illness for as long as one week after aerosol exposures of human populations to F. tularensis.
Collapse
Affiliation(s)
- Gene McClellan
- Applied Research Associates, Inc., Arlington Division, Arlington, VA, USA
| | | | - David Crary
- Applied Research Associates, Inc., Arlington Division, Arlington, VA, USA
| | - Alec Thurman
- Applied Research Associates, Inc., Arlington Division, Arlington, VA, USA
| | - Brandolyn Thran
- Formerly U.S. Army Public Health Command, Environmental Health Risk Assessment Program, Aberdeen Proving Ground, MD, USA; now at Open-Gate Foundation, Elko, NV, USA
| |
Collapse
|
40
|
Mansour AA, Banik S, Suresh RV, Kaur H, Malik M, McCormick AA, Bakshi CS. An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia. Front Microbiol 2018; 9:1195. [PMID: 29922267 PMCID: PMC5996085 DOI: 10.3389/fmicb.2018.01195] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Accepted: 05/16/2018] [Indexed: 12/22/2022] Open
Abstract
Francisella tularensis, the causative agent of the fatal human disease known as tularemia is classified as a Category A Select Agent by the Centers for Disease Control. No licensed vaccine is currently available for prevention of tularemia in the United States. Previously, we published that a tri-antigen tobacco mosaic virus (TMV) vaccine confers 50% protection in immunized mice against respiratory tularemia caused by F. tularensis. In this study, we refined the TMV-vaccine formulation to improve the level of protection in immunized C57BL/6 mice against respiratory tularemia. We developed a tetra-antigen vaccine by conjugating OmpA, DnaK, Tul4, and SucB proteins of Francisella to TMV. CpG was also included in the vaccine formulation as an adjuvant. Primary intranasal (i.n.) immunization followed by two booster immunizations with the tetra-antigen TMV vaccine protected 100% mice against i.n. 10LD100 challenges dose of F. tularensis live vaccine strain (LVS). Mice receiving three immunization doses of tetra-antigen TMV vaccine showed only transient body weight loss, cleared the infection rapidly, and showed minimal histopathological lesions in lungs, liver, and spleen following a lethal respiratory challenge with F. tularensis LVS. Mice immunized with the tetra-antigen TMV vaccine also induced strong ex vivo recall responses and were protected against a lethal challenge as late as 163 days post-primary immunization. Three immunization with the tetra-antigen TMV vaccine also induced a stronger humoral immune response predominated by IgG1, IgG2b, and IgG2c antibodies than mice receiving only a single or two immunizations. Remarkably, a single dose protected 40% of mice, while two doses protected 80% of mice from lethal pathogen challenge. Immunization of Interferon-gamma (IFN-γ)-deficient mice with the tetra-antigen TMV vaccine demonstrated an absolute requirement of IFN-γ for the generation of protective immune response against a lethal respiratory challenge with F. tularensis LVS. Collectively, this study further demonstrates the feasibility of TMV as an efficient platform for the delivery of multiple F. tularensis antigens and that tetra-antigen TMV vaccine formulation provides complete protection, and induces long-lasting protective and memory immune responses against respiratory tularemia caused by F. tularensis LVS.
Collapse
Affiliation(s)
- Ahd A Mansour
- Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, United States
| | - Sukalyani Banik
- Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, United States
| | - Ragavan V Suresh
- Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, United States
| | - Hardeep Kaur
- College of Pharmacy, Touro University California, Vallejo, CA, United States
| | - Meenakshi Malik
- Department of Basic and Clinical Sciences, School of Arts and Sciences, Albany College of Pharmacy and Health Sciences, Albany, NY, United States
| | - Alison A McCormick
- College of Pharmacy, Touro University California, Vallejo, CA, United States
| | - Chandra S Bakshi
- Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, United States
| |
Collapse
|
41
|
Guina T, Lanning LL, Omland KS, Williams MS, Wolfraim LA, Heyse SP, Houchens CR, Sanz P, Hewitt JA. The Cynomolgus Macaque Natural History Model of Pneumonic Tularemia for Predicting Clinical Efficacy Under the Animal Rule. Front Cell Infect Microbiol 2018; 8:99. [PMID: 29670861 PMCID: PMC5893833 DOI: 10.3389/fcimb.2018.00099] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Accepted: 03/16/2018] [Indexed: 11/25/2022] Open
Abstract
Francisella tularensis is a highly infectious Gram-negative bacterium that is the etiologic agent of tularemia in animals and humans and a Tier 1 select agent. The natural incidence of pneumonic tularemia worldwide is very low; therefore, it is not feasible to conduct clinical efficacy testing of tularemia medical countermeasures (MCM) in human populations. Development and licensure of tularemia therapeutics and vaccines need to occur under the Food and Drug Administration's (FDA's) Animal Rule under which efficacy studies are conducted in well-characterized animal models that reflect the pathophysiology of human disease. The Tularemia Animal Model Qualification (AMQ) Working Group is seeking qualification of the cynomolgus macaque (Macaca fascicularis) model of pneumonic tularemia under Drug Development Tools Qualification Programs with the FDA based upon the results of studies described in this manuscript. Analysis of data on survival, average time to death, average time to fever onset, average interval between fever and death, and bacteremia; together with summaries of clinical signs, necropsy findings, and histopathology from the animals exposed to aerosolized F. tularensis Schu S4 in five natural history studies and one antibiotic efficacy study form the basis for the proposed cynomolgus macaque model. Results support the conclusion that signs of pneumonic tularemia in cynomolgus macaques exposed to 300-3,000 colony forming units (cfu) aerosolized F. tularensis Schu S4, under the conditions described herein, and human pneumonic tularemia cases are highly similar. Animal age, weight, and sex of animals challenged with 300-3,000 cfu Schu S4 did not impact fever onset in studies described herein. This study summarizes critical parameters and endpoints of a well-characterized cynomolgus macaque model of pneumonic tularemia and demonstrates this model is appropriate for qualification, and for testing efficacy of tularemia therapeutics under Animal Rule.
Collapse
Affiliation(s)
- Tina Guina
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Lynda L. Lanning
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | | | - Mark S. Williams
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Larry A. Wolfraim
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Stephen P. Heyse
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Christopher R. Houchens
- Biomedical Advanced Research and Development Authority, Department of Health and Human Services, Washington, DC, United States
| | - Patrick Sanz
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Judith A. Hewitt
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| |
Collapse
|
42
|
Stidham RA, Freeman DB, von Tersch RL, Sullivan PJ, Tostenson SD. Epidemiological Review of Francisella Tularensis: A Case Study in the Complications of Dual Diagnoses. PLOS CURRENTS 2018; 10:ecurrents.outbreaks.8eb0b55f377abc2d250314bbb8fc9d6d. [PMID: 29399382 PMCID: PMC5774973 DOI: 10.1371/currents.outbreaks.8eb0b55f377abc2d250314bbb8fc9d6d] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Tularemia is a rare but potentially fatal disease that develops in numerous wild and domestic animals, including lagomorphs, rodents, cats, and humans. Francisella tularensis bacterium, the causative agent of tularemia, was identified by veterinary personnel at Fort Riley, Kansas during a routine post-mortum evaluation of a domestic feline. However, before formal diagnosis was confirmed, the sample was sent and prepared for rabies testing at the Department of Defense (DoD) U.S. Army Public Health Command Central (PHC-C), Food Analysis and Diagnostic Laboratory (FADL). This case report provides insight on how veterinarian staff and laboratory personnel can clinically manage esoteric, unexplained, or post-mortum examinations. The epidemiologic characteristics of tularemia, F. tularensis as an organism of military interest, potential laboratory management of F. tularensis, and clinical findings on a case of feline tularemia are discussed. It further raises questions as to whether or not dead animals should be treated as sentinels and be pre-screened for select agents, especially in instances of dual diagnoses. METHODS A necropsy was performed on the cat by the Fort Riley veterinarian, DNA extraction and PCR analyses were conducted by FADL microbiologists, histology and immunohistology analyses were conducted by the Kansas State Veterinary Diagnostic Laboratory, and feline tissue and blood were sent to the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for confirmatory testing and strain identification of tularemia. RESULTS Tularemia was identified in the spleen of the cat by the Fort Riley veterinarian and during the histological sampling of the spleen by the Kansas State Veterinary Diagnostic Laboratory. A specific subsequent real-time polymerase chain reaction (RT-PCR) in vitro diagnostic detection of target DNA sequences of F. tularensis was conducted by the FADL microbiologists using a Joint Biological Agent Identification and Diagnostic System (JBAIDS) Tularemia Detection Kit to detect a presumptive qualitative result to detect tularemia in feline and blood samples. USAMRIID also performed RT-PCR and identified genomic DNA from F. tularensis Type A, (SPL15.013.02), thus confirming the FADL's initial presumptive result of F. tularensis. USAMRIID attempted to culture F. tularensis from three samples (swab, feline tissue, and transfer pipette tip), but no growth consistent with F. tularensis was observed on the cysteine heart agar with sheep blood and antibiotics (CHAB) and chocolate (CHOC) plates. DISCUSSIONS Our case study of a dual diagnosis of presumptive F. tularensis and possible rabies exposure transmission from a pet cat to its owner provides insight on how veterinarian staff and laboratory personnel can clinically manage esoteric, unexplained, or post-mortum examinations. Our case study also demonstrates the obligation for cooperation between animal health, human health, and public health professionals in the management of zoonotic diseases.
Collapse
Affiliation(s)
- Ralph Anthony Stidham
- Epidemiology and Disease Surveillance, US Army Public Health Command-Central, JBSA Fort Sam Houston, Texas, United States of America
| | - David B Freeman
- † Laboratory, Diagnostics Section, US Army Public Health Command-Central, JBSA Fort Sam Houston, Texas, United States of America
| | - Robert L von Tersch
- † Office of the Commander (Commander), US Army Public Health Command-Central, JBSA Fort Sam Houston, Texas, United States of America
| | - Peter J Sullivan
- Veterinarian Services, Fort Riley Veterinary Treatment Facility, Fort Riley, Kansas, United States of America
| | - Samantha D Tostenson
- Special Pathogens Laboratory, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, United States of America
| |
Collapse
|
43
|
Brock SR, Parmely MJ. Francisella tularensis Confronts the Complement System. Front Cell Infect Microbiol 2017; 7:523. [PMID: 29312899 PMCID: PMC5742141 DOI: 10.3389/fcimb.2017.00523] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Accepted: 12/08/2017] [Indexed: 12/30/2022] Open
Abstract
Francisella tularensis has developed a number of effective evasion strategies to counteract host immune defenses, not the least of which is its ability to interact with the complement system to its own advantage. Following exposure of the bacterium to fresh human serum, complement is activated and C3b and iC3b can be found covalently attached to the bacterial surface. However, the lipopolysaccharide and capsule of the F. tularensis cell wall prevent complement-mediated lysis and endow the bacterium with serum resistance. Opsonization of F. tularensis with C3 greatly increases its uptake by human neutrophils, dendritic cells and macrophages. Uptake occurs by an unusual looping morphology in human macrophages. Complement receptor 3 is thought to play an important role in opsonophagocytosis by human macrophages, and signaling through this receptor can antagonize Toll-like receptor 2-initiated macrophage activation. Complement C3 also determines the survival of infected human macrophages and perhaps other cell types. C3-opsonization of F. tularensis subsp. tularensis strain SCHU S4 results in greatly increased death of infected human macrophages, which requires more than complement receptor engagement and is independent of the intracellular replication by the pathogen. Given its entry into the cytosol of host cells, F. tularensis has the potential for a number of other complement-mediated interactions. Studies on the uptake C3-opsonized adenovirus have suggested the existence of a C3 sensing system that initiates cellular responses to cytosolic C3b present on invading microbes. Here we propose that C3 peptides enter the cytosol of human macrophages following phagosome escape of F. tularensis and are recognized as intruding molecular patterns that signal host cell death. With the discovery of new roles for intracellular C3, a better understanding of tularemia pathogenesis is likely to emerge.
Collapse
Affiliation(s)
- Susan R Brock
- Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, KS, United States
| | - Michael J Parmely
- Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, KS, United States
| |
Collapse
|
44
|
Complement C3 as a Prompt for Human Macrophage Death during Infection with Francisella tularensis Strain SCHU S4. Infect Immun 2017; 85:IAI.00424-17. [PMID: 28739830 DOI: 10.1128/iai.00424-17] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Accepted: 07/18/2017] [Indexed: 02/06/2023] Open
Abstract
Tularemia is caused by the Gram-negative bacterial pathogen Francisella tularensis Infection of macrophages and their subsequent death are believed to play important roles in the progression of disease. Because complement is a particularly effective opsonin for Francisella, we asked whether complement-dependent uptake of F. tularensis strain SCHU S4 affects the survival of primary human macrophages during infection. Complement component C3 was found to be an essential opsonin in human serum not only for greatly increased uptake of SCHU S4 but also for the induction of macrophage death. Single-cell analysis also revealed that macrophage death did not require a high intracellular bacterial burden. In the presence of C3, macrophage death was observed at 24 h postinfection in a quarter of the macrophages that contained only 1 to 5 bacterial cells. Macrophages infected in the absence of C3 rarely underwent cell death, even when they contained large numbers of bacteria. The need for C3, but not extensive replication of the pathogen, was confirmed by infections with SCHU S4 ΔpurMCD, a mutant capable of phagosome escape but of only limited cytosolic replication. C3-dependent Francisella uptake alone was insufficient to induce macrophage death, as evidenced by the failure of the phagosome escape-deficient mutant SCHU S4 ΔfevR to induce cell death despite opsonization with C3. Together, these findings indicate that recognition of C3-opsonized F. tularensis, but not extensive cytosolic replication, plays an important role in regulating macrophage viability during intracellular infections with type A F. tularensis.
Collapse
|
45
|
Sutera V, Hoarau G, Renesto P, Caspar Y, Maurin M. In vitro and in vivo evaluation of fluoroquinolone resistance associated with DNA gyrase mutations in Francisella tularensis, including in tularaemia patients with treatment failure. Int J Antimicrob Agents 2017; 50:377-383. [PMID: 28689870 DOI: 10.1016/j.ijantimicag.2017.03.022] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2016] [Revised: 03/20/2017] [Accepted: 03/22/2017] [Indexed: 01/23/2023]
Abstract
Fluoroquinolones (FQs) are highly effective for treating tularaemia, a zoonosis caused by Francisella tularensis, but failures and relapses remain common in patients with treatment delay or immunocompromised status. FQ-resistant strains of F. tularensis harboring mutations in the quinolone-resistance determining region (QRDR) of gyrA and gyrB, the genes encoding subunits A and B of DNA gyrase, have been selected in vitro. Such mutants have never been isolated from humans as this microorganism is difficult to culture. In this study, the presence of FQ-resistant mutants of F. tularensis was assessed in tularaemia patients using combined culture- and PCR-based approaches. We analyzed 42 F. tularensis strains and 82 tissue samples collected from 104 tularaemia cases, including 32 (30.7%) with FQ treatment failure or relapse. Forty F. tularensis strains and 55 clinical samples were obtained before any FQ treatment, while 2 strains and 15 tissue samples were collected after treatment. FQ resistance was evaluated by the minimum inhibitory concentration (MIC) for the bacterial strains, and by newly developed PCR-based methods targeting the gyrA and gyrB QRDRs for both the bacterial strains and the clinical samples. None of the F. tularensis strains displayed an increased MIC compared with FQ-susceptible controls. Neither gyrA nor gyrB QRDR mutation was found in bacterial strains and tissue samples tested, including those from patients with FQ treatment failure or relapse. Further phenotypic and genetic resistance traits should be explored to explain the poor clinical response to FQ treatment in such tularaemia patients.
Collapse
Affiliation(s)
- V Sutera
- Centre National de Référence des Francisella, Laboratoire de Bactériologie-Hygiène Hospitalière, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, CS 10217, 38043 Grenoble Cedex 9, France; Laboratoire Techniques de l'Ingénierie Médicale et de la Complexité-Informatique, Mathématiques et Applications (TIMC-IMAG), Université Grenoble Alpes, CS 10170, 38042 Grenoble cedex 9, France; Unité Mixte de Recherche 5525, Centre National de la Recherche Scientifique, 38042 Grenoble cedex 9, France
| | - G Hoarau
- Centre National de Référence des Francisella, Laboratoire de Bactériologie-Hygiène Hospitalière, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, CS 10217, 38043 Grenoble Cedex 9, France; Laboratoire Techniques de l'Ingénierie Médicale et de la Complexité-Informatique, Mathématiques et Applications (TIMC-IMAG), Université Grenoble Alpes, CS 10170, 38042 Grenoble cedex 9, France; Unité Mixte de Recherche 5525, Centre National de la Recherche Scientifique, 38042 Grenoble cedex 9, France
| | - P Renesto
- Laboratoire Techniques de l'Ingénierie Médicale et de la Complexité-Informatique, Mathématiques et Applications (TIMC-IMAG), Université Grenoble Alpes, CS 10170, 38042 Grenoble cedex 9, France; Unité Mixte de Recherche 5525, Centre National de la Recherche Scientifique, 38042 Grenoble cedex 9, France
| | - Y Caspar
- Centre National de Référence des Francisella, Laboratoire de Bactériologie-Hygiène Hospitalière, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, CS 10217, 38043 Grenoble Cedex 9, France; Laboratoire Techniques de l'Ingénierie Médicale et de la Complexité-Informatique, Mathématiques et Applications (TIMC-IMAG), Université Grenoble Alpes, CS 10170, 38042 Grenoble cedex 9, France; Unité Mixte de Recherche 5525, Centre National de la Recherche Scientifique, 38042 Grenoble cedex 9, France
| | - M Maurin
- Centre National de Référence des Francisella, Laboratoire de Bactériologie-Hygiène Hospitalière, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble Alpes, CS 10217, 38043 Grenoble Cedex 9, France; Laboratoire Techniques de l'Ingénierie Médicale et de la Complexité-Informatique, Mathématiques et Applications (TIMC-IMAG), Université Grenoble Alpes, CS 10170, 38042 Grenoble cedex 9, France; Unité Mixte de Recherche 5525, Centre National de la Recherche Scientifique, 38042 Grenoble cedex 9, France.
| |
Collapse
|
46
|
Schmitt DM, Barnes R, Rogerson T, Haught A, Mazzella LK, Ford M, Gilson T, Birch JWM, Sjöstedt A, Reed DS, Franks JM, Stolz DB, Denvir J, Fan J, Rekulapally S, Primerano DA, Horzempa J. The Role and Mechanism of Erythrocyte Invasion by Francisella tularensis. Front Cell Infect Microbiol 2017; 7:173. [PMID: 28536678 PMCID: PMC5423315 DOI: 10.3389/fcimb.2017.00173] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Accepted: 04/21/2017] [Indexed: 01/06/2023] Open
Abstract
Francisella tularensis is an extremely virulent bacterium that can be transmitted naturally by blood sucking arthropods. During mammalian infection, F. tularensis infects numerous types of host cells, including erythrocytes. As erythrocytes do not undergo phagocytosis or endocytosis, it remains unknown how F. tularensis invades these cells. Furthermore, the consequence of inhabiting the intracellular space of red blood cells (RBCs) has not been determined. Here, we provide evidence indicating that residing within an erythrocyte enhances the ability of F. tularensis to colonize ticks following a blood meal. Erythrocyte residence protected F. tularensis from a low pH environment similar to that of gut cells of a feeding tick. Mechanistic studies revealed that the F. tularensis type VI secretion system (T6SS) was required for erythrocyte invasion as mutation of mglA (a transcriptional regulator of T6SS genes), dotU, or iglC (two genes encoding T6SS machinery) severely diminished bacterial entry into RBCs. Invasion was also inhibited upon treatment of erythrocytes with venom from the Blue-bellied black snake (Pseudechis guttatus), which aggregates spectrin in the cytoskeleton, but not inhibitors of actin polymerization and depolymerization. These data suggest that erythrocyte invasion by F. tularensis is dependent on spectrin utilization which is likely mediated by effectors delivered through the T6SS. Our results begin to elucidate the mechanism of a unique biological process facilitated by F. tularensis to invade erythrocytes, allowing for enhanced colonization of ticks.
Collapse
Affiliation(s)
- Deanna M Schmitt
- Department of Natural Sciences and Mathematics, West Liberty UniversityWest Liberty, WV, USA
| | - Rebecca Barnes
- Department of Natural Sciences and Mathematics, West Liberty UniversityWest Liberty, WV, USA
| | - Taylor Rogerson
- Department of Natural Sciences and Mathematics, West Liberty UniversityWest Liberty, WV, USA
| | - Ashley Haught
- Department of Natural Sciences and Mathematics, West Liberty UniversityWest Liberty, WV, USA
| | - Leanne K Mazzella
- Department of Natural Sciences and Mathematics, West Liberty UniversityWest Liberty, WV, USA
| | - Matthew Ford
- Department of Natural Sciences and Mathematics, West Liberty UniversityWest Liberty, WV, USA
| | - Tricia Gilson
- Department of Natural Sciences and Mathematics, West Liberty UniversityWest Liberty, WV, USA
| | - James W-M Birch
- Department of Natural Sciences and Mathematics, West Liberty UniversityWest Liberty, WV, USA
| | - Anders Sjöstedt
- Department of Clinical Microbiology, Clinical Bacteriology, and Laboratory for Molecular Infection Medicine Sweden, Umeå UniversityUmeå, Sweden
| | - Douglas S Reed
- Regional Biocontainment Laboratory, Center for Vaccine Research, University of PittsburghPittsburgh, PA, USA
| | - Jonathan M Franks
- Center for Biologic Imaging, University of Pittsburgh School of MedicinePittsburgh, PA, USA
| | - Donna B Stolz
- Center for Biologic Imaging, University of Pittsburgh School of MedicinePittsburgh, PA, USA
| | - James Denvir
- Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall UniversityHuntington, WV, USA
| | - Jun Fan
- Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall UniversityHuntington, WV, USA
| | - Swanthana Rekulapally
- Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall UniversityHuntington, WV, USA
| | - Donald A Primerano
- Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall UniversityHuntington, WV, USA
| | - Joseph Horzempa
- Department of Natural Sciences and Mathematics, West Liberty UniversityWest Liberty, WV, USA
| |
Collapse
|
47
|
Ruehle B, Clemens DL, Lee BY, Horwitz MA, Zink JI. A Pathogen-Specific Cargo Delivery Platform Based on Mesoporous Silica Nanoparticles. J Am Chem Soc 2017; 139:6663-6668. [PMID: 28437093 DOI: 10.1021/jacs.7b01278] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We present a synthetic approach to a highly pathogen-selective detection and delivery platform based on the interaction of an antibody nanovalve with a tetrasaccharide from the O-antigen of the lipopolysaccharide (LPS) of Francisella tularensis bacteria, a Tier 1 Select Agent of bioterrorism. Different design considerations are explored, and proof-of-concept for highly pathogen-specific cargo release from mesoporous silica nanoparticles is demonstrated by comparisons of the release of a signal transducer and model drug by LPS from F. tularensis vs Pseudomonas aeruginosa and by F. tularensis live bacteria vs the closely related bacterium Francisella novocida. In addition to the specific response to a biowarfare agent, treatment of infectious diseases in general could benefit tremendously from a delivery platform that releases its antibiotic payload only at the site of infection and only in the presence of the target pathogen, thereby minimizing off-target toxicities.
Collapse
Affiliation(s)
- Bastian Ruehle
- Department of Chemistry and Biochemistry, ‡California NanoSystems Institute, and §Division of Infectious Diseases, Department of Medicine, University of California , Los Angeles, California 90095, United States
| | - Daniel L Clemens
- Department of Chemistry and Biochemistry, ‡California NanoSystems Institute, and §Division of Infectious Diseases, Department of Medicine, University of California , Los Angeles, California 90095, United States
| | - Bai-Yu Lee
- Department of Chemistry and Biochemistry, ‡California NanoSystems Institute, and §Division of Infectious Diseases, Department of Medicine, University of California , Los Angeles, California 90095, United States
| | - Marcus A Horwitz
- Department of Chemistry and Biochemistry, ‡California NanoSystems Institute, and §Division of Infectious Diseases, Department of Medicine, University of California , Los Angeles, California 90095, United States
| | - Jeffrey I Zink
- Department of Chemistry and Biochemistry, ‡California NanoSystems Institute, and §Division of Infectious Diseases, Department of Medicine, University of California , Los Angeles, California 90095, United States
| |
Collapse
|
48
|
Foster CL, Badlam J, De Groote MA, Chan ED. A 65-Year-Old Groundskeeper With High Fever, Pulmonary Nodules, and Thoracic Lymphadenopathy. Chest 2017; 149:e191-4. [PMID: 27287596 DOI: 10.1016/j.chest.2015.12.035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Revised: 12/14/2015] [Accepted: 12/31/2015] [Indexed: 12/01/2022] Open
Abstract
A 65-year-old man with treated latent tuberculous infection presented with 1 week of fevers (up to 39.6°C), chills, headache, lightheadedness, and malaise. He reported a chronic, nonproductive cough without hemoptysis but denied other localizing symptoms, sick contacts, or recent travel. He lived in an urban area in eastern Colorado and owned one healthy dog but otherwise denied known animal exposures. He was a retired oil driller who had worked in southern Arizona, New Mexico, and northern Mexico (Sonora region). Other travel included 3 years in the early 1970s working as a military aircraft mechanic in Vietnam, Laos, and Thailand. Six weeks prior to admission, he began work as a groundskeeper on a golf course that had experienced recent flooding, using a riding mower and exposing himself to airborne dust and organic debris. He smoked a pipe daily for 30 years but quit 2 months prior to presentation, although he continued to smoke marijuana weekly. He denied intravenous drug use.
Collapse
Affiliation(s)
- Clayton L Foster
- Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, CO
| | - Jessica Badlam
- Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
| | - Mary Ann De Groote
- Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO
| | - Edward D Chan
- Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; Department of Medicine and Academic Affairs, National Jewish Health, Denver, CO; Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO.
| |
Collapse
|
49
|
Caspar Y, Maurin M. Francisella tularensis Susceptibility to Antibiotics: A Comprehensive Review of the Data Obtained In vitro and in Animal Models. Front Cell Infect Microbiol 2017; 7:122. [PMID: 28443249 PMCID: PMC5386985 DOI: 10.3389/fcimb.2017.00122] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Accepted: 03/27/2017] [Indexed: 11/13/2022] Open
Abstract
The antibiotic classes that are recommended for tularaemia treatment are the aminoglycosides, the fluoroquinolones and the tetracyclines. However, cure rates vary between 60 and 100% depending on the antibiotic used, the time to appropriate antibiotic therapy setup and its duration, and the presence of complications, such as lymph node suppuration. Thus, antibiotic susceptibility testing (AST) of F. tularensis strains remains of primary importance for detection of the emergence of antibiotic resistances to first-line drugs, and to test new therapeutic alternatives. However, the AST methods reported in the literature were poorly standardized between studies and AST data have not been previously evaluated in a comprehensive and comparative way. The aim of the present review was to summarize experimental data on antibiotic susceptibilities of F. tularensis obtained in acellular media, cell models and animal models since the introduction of fluoroquinolones in the treatment of tularaemia in 1989. We compiled MIC data of 33 antibiotics (including aminoglycosides, fluoroquinolones, tetracyclines, macrolides, β-lactams, chloramphenicol, rifampicin, and linezolid) against 900 F. tularensis strains (504 human strains), including 107 subsp. tularensis (type A), 789 subsp. holarctica (type B) and four subsp. mediasiatica strains, using various AST methods. Specific culture media were identified or confirmed as unsuitable for AST of F. tularensis. Overall, MICs were the lowest for ciprofloxacin (≤ 0.002-0.125 mg/L) and levofloxacin, and ranged from ≤ 0.016 to 2 mg/L for gentamicin, and 0.064 to 4 mg/L for doxycycline. No resistant strain to any of these antibiotics was reported. Fluoroquinolones also exhibited a bactericidal activity against intracellular F. tularensis and lower relapse rates in animal models when compared with the bacteriostatic compound doxycycline. As expected, lower MIC values were found for macrolides against type A and biovar I type B strains, compared to biovar II type B strains. The macrolides were more effective against F. tularensis grown in phagocytic cells than in acellular media.
Collapse
Affiliation(s)
- Yvan Caspar
- Laboratoire de Bactériologie-Hygiène Hospitalière, Département des agents infectieux, Centre National de Référence des Francisella, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble AlpesGrenoble, France
- Université Grenoble Alpes, Centre National de la Recherche Scientifique, TIMC-IMAGGrenoble, France
| | - Max Maurin
- Laboratoire de Bactériologie-Hygiène Hospitalière, Département des agents infectieux, Centre National de Référence des Francisella, Institut de Biologie et de Pathologie, Centre Hospitalier Universitaire Grenoble AlpesGrenoble, France
- Université Grenoble Alpes, Centre National de la Recherche Scientifique, TIMC-IMAGGrenoble, France
| |
Collapse
|
50
|
Lester Rothfeldt LK, Jacobs RF, Wheeler JG, Weinstein S, Haselow DT. Variation in Tularemia Clinical Manifestations-Arkansas, 2009-2013. Open Forum Infect Dis 2017; 4:ofx027. [PMID: 28480295 PMCID: PMC5414106 DOI: 10.1093/ofid/ofx027] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Accepted: 02/13/2017] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Francisella tularensis, although naturally occurring in Arkansas, is also a Tier 1 select agent and potential bioterrorism threat. As such, tularemia is nationally notifiable and mandatorily reported to the Arkansas Department of Health. We examined demographic and clinical characteristics among reported cases and outcomes to improve understanding of the epidemiology of tularemia in Arkansas. METHODS Surveillance records on all tularemia cases investigated during 2009-2013 were reviewed. RESULTS The analytic dataset was assembled from 284 tularemia reports, yielding 138 probable and confirmed tularemia cases during 2009-2013. Arthropod bite was identified in 77% of cases. Of 7 recognized tularemia manifestations, the typhoidal form was reported in 47% of cases, approximately double the proportion of the more classic manifestation, lymphadenopathy. Overall, 41% of patients were hospitalized; 3% died. The typhoidal form appeared to be more severe, accounting for the majority of sepsis and meningitis cases, hospitalizations, and deaths. Among patients with available antibiotic data, 88% received doxycycline and 12% received gentamicin. CONCLUSIONS Contrary to expectation, lymphadenopathy was not the most common manifestation observed in our registry. Instead, our patients were more likely to report only generalized typhoidal symptoms. Using lymphadenopathy as a primary symptom to initiate tularemia testing may be an insensitive diagnostic strategy and result in unrecognized cases. In endemic areas such as Arkansas, suspicion of tularemia should be high, especially during tick season. Outreach to clinicians describing the full range of presenting symptoms may help address misperceptions about tularemia.
Collapse
Affiliation(s)
- Laura K Lester Rothfeldt
- Epidemic Intelligence Service, Division of Scientific and Professional Development, Centers for Disease Control and Prevention, Atlanta, Georgia
- Arkansas Department of Health, Little Rock
| | - Richard F Jacobs
- Arkansas Children's Hospital, Little Rock; and
- University of Arkansas for Medical Sciences, Little Rock
| | - J Gary Wheeler
- Arkansas Department of Health, Little Rock
- Arkansas Children's Hospital, Little Rock; and
- University of Arkansas for Medical Sciences, Little Rock
| | | | - Dirk T Haselow
- Arkansas Department of Health, Little Rock
- Arkansas Children's Hospital, Little Rock; and
- University of Arkansas for Medical Sciences, Little Rock
| |
Collapse
|